var title_f30_45_31440="Management algorithm for dengue fever with hypotensive shock";
var content_f30_45_31440=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 641px\">",
"   <div class=\"ttl\">",
"    Algorithm for hypotensive shock and dengue fever",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 621px; height: 672px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Isotonic crystalloid solutions include normal saline (0.9 percent ) and Ringer's lactate. 5 percent albumin is the most commonly used colloid solution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dengue: Guidelines for diagnosis, treatment, prevention and control. World Health Organization, Geneva, Switzerland, 2009. Copyright &copy; 2009 WHO. Available at:",
"     <a href=\"file://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf\" target=\"_blank\">",
"      file://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_45_31440=[""].join("\n");
var outline_f30_45_31440=null;
var title_f30_45_31441="Overhead arm raise exercise video";
var content_f30_45_31441=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1070px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PC/51229/Overhead_arm_raise_video.mp4?title=Overhead+arm+raise+exercise+video\" style=\"width:480px;height:336px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strength exercise video: Overhead arm raise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This exercise will strengthen your shoulders and arms. It should make swimming and other activities such as lifting and carrying grandchildren easier.",
"    <br>",
"     <ol>",
"      <li>",
"       You can do this exercise while standing or sitting in a sturdy, armless chair.",
"      </li>",
"      <li>",
"       Keep your feet flat on the floor, shoulder-width apart.",
"      </li>",
"      <li>",
"       Hold weights* at your sides at shoulder height with palms facing forward. Breathe in slowly.",
"      </li>",
"      <li>",
"       Slowly breathe out as you raise both arms up over your head keeping your elbows slightly bent.",
"      </li>",
"      <li>",
"       Hold the position for one second.",
"      </li>",
"      <li>",
"       Breathe in as you slowly lower your arms.",
"      </li>",
"      <li>",
"       Repeat 10 to 15 times.",
"      </li>",
"      <li>",
"       Rest; then repeat 10 to 15 more times.",
"      </li>",
"     </ol>",
"     As you progress, use a heavier weight and alternate arms until you can lift the weight confortably with both arms.",
"     <div class=\"footnotes\">",
"      * Hand-held weights or household items (soup cans, bottles of water).",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_45_31441=[""].join("\n");
var outline_f30_45_31441=null;
var title_f30_45_31442="Chondroblastoma knee";
var content_f30_45_31442=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chondroblastoma of the knee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 511px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intercondylar (Tunnel), Knee, Chondroblastoma. A well-defined radiolucent lesion is present within the medial femoral condyle (arrows). This lesion was almost non-detectable on the routine AP view but is shown more clearly on the intercondylar view, because the femoral surface is less tangential to the incident beam.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_45_31442=[""].join("\n");
var outline_f30_45_31442=null;
var title_f30_45_31443="Blood flow erection PI";
var content_f30_45_31443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Penile blood flow in erection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cross-section of corpora cavernosae illustrating penile blood flow in the flaccid and erect state. As intracavernosal pressure rises, emissary veins are occluded to maintain erectile function.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_45_31443=[""].join("\n");
var outline_f30_45_31443=null;
var title_f30_45_31444="Seated knee chest PI";
var content_f30_45_31444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Seated knee-chest exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 487px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The seated knee-chest exercise is performed while seated on a chair; it s an alternative exercise for those who do not perceive a stretching sensation in the low back during the standard knee to chest exercises (perhaps due to hypermobility of the hips). Each stretch is held for 5 to 10 seconds; 6 to 10 repetitions are done twice daily.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_45_31444=[""].join("\n");
var outline_f30_45_31444=null;
var title_f30_45_31445="Sunburn on face";
var content_f30_45_31445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Sunburn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema and scale are present on the sun exposed areas of the skin. Note the relative sparing in the shadow areas of the nasolabial folds and infranasal skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_45_31445=[""].join("\n");
var outline_f30_45_31445=null;
var title_f30_45_31446="Cloxacillin: Drug information";
var content_f30_45_31446=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cloxacillin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/37/25172?source=see_link\">",
"    see \"Cloxacillin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F153884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cloxi&reg;;",
"     </li>",
"     <li>",
"      Novo-Cloxin;",
"     </li>",
"     <li>",
"      Nu-Cloxi",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F153901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Penicillin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F153887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose and duration of therapy can vary depending on infecting organism, severity of infection, and clinical response of patient. Treat severe staphylococcal infections for at least 14 days; endocarditis and osteomyelitis require an extended duration of therapy for 4-6 weeks. The intravenous route should be used for severe infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Susceptible infections (manufacturer&rsquo;s labeling):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: 250-500 mg every 6 hours (maximum adult dose: 6 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M., I.V.: 250-500 mg every 6 hours (maximum adult dose: 6 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Dosing recommendations of World Health Organization unless otherwise noted:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Arthritis (septic), methicillin-sensitive",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      (MSSA) (unlabeled dosing):",
"     </b>",
"     I.M., I.V.: 2 g every 6 hours for 2-3 weeks;",
"     <b>",
"      Note:",
"     </b>",
"     Oral therapy of 1 g every 6 hours may be used to complete therapy if parenteral therapy is discontinued prior to 2-3 week duration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Endocarditis (MSSA) (unlabeled dosing):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Native valve:",
"     </i>",
"     2 g every 4 hours for 6 weeks; may give with gentamicin for initial 5 days (Choudri, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Prosthetic valve:",
"     </i>",
"     2 g every 4 hours for 6 weeks; give with gentamicin for 2 weeks and rifampin for 6 weeks (Choudri, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Uncomplicated endocarditis in I.V. drug users:",
"     </i>",
"     2 g every 4 hours for 4 weeks and gentamicin for initial 5 days",
"     <b>",
"      or",
"     </b>",
"     2 g every 4 hours and gentamicin both given for 2 weeks total (Choudri, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Osteomyelitis (MSSA) (unlabeled dosing):",
"     </b>",
"     I.M., I.V.: 2 g every 6 hours for 4-6 weeks (preferred)",
"     <b>",
"      or",
"     </b>",
"     for a minimum of 14 days,",
"     <b>",
"      followed by",
"     </b>",
"     1 g every 6 hours orally to complete 4-6 weeks of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Pneumonia (MSSA) (unlabeled dosing):",
"     </b>",
"     I.M., I.V.: 1-2 g every 6 hours for 10-14 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F153895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose and duration of therapy can vary depending on infecting organism, severity of infection, and clinical response of patient. Treat severe staphylococcal infections for at least 14 days; endocarditis and osteomyelitis require an extended duration of therapy for 4-6 weeks. The intravenous route should be used for severe infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Susceptible infections (manufacturer&rsquo;s labeling):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &le;20 kg: 25-50 mg/kg/day in divided doses every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt;20 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &le;20 kg: 25-50 mg/kg/day in divided doses every 6 hours; up to 200 mg/kg/day has been used in some studies for severe infections (Nunn, 2007; St. John, 1981)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt;20 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Dosing recommendations of World Health Organization unless otherwise noted:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Arthritis (septic), methicillin-sensitive",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      (MSSA) (unlabeled dosing):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Children 2 months to 5 years: I.M., I.V.: 25-50 mg/kg (maximum: 2 g) every 4-6 hours given with ceftriaxone until clinical improvement,",
"     <b>",
"      followed by",
"     </b>",
"     oral therapy: 12.5 mg/kg (maximum: 500 mg) every 6 hours; total duration of therapy 2-3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Children &gt;5 years: I.M., I.V.: 25-50 mg/kg (maximum: 2 g) every 4-6 hours (maximum daily dose: 12 g/day) until clinical improvement,",
"     <b>",
"      followed by",
"     </b>",
"     oral therapy: 25 mg/kg (maximum: 500 mg) every 6 hours; total duration of therapy 2-3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Endocarditis (MSSA) (unlabeled dosing):",
"     </b>",
"     I.V.: 50 mg/kg (maximum: 2 g) every 4 hours for 6 weeks; give with gentamicin for initial 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Osteomyelitis (MSSA) (unlabeled dosing):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Children 2 months to 5 years: I.M., I.V.: 25-50 mg/kg (maximum: 2 g) every 4-6 hours given with ceftriaxone until clinical improvement,",
"     <b>",
"      followed by",
"     </b>",
"     oral therapy: 12.5 mg/kg (maximum: 500 mg) every 6 hours; total duration of therapy 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Children &gt;5 years: I.M., I.V.: 25-50 mg/kg (maximum: 2 g) every 4-6 hours (maximum daily dose: 12 g/day) until clinical improvement,",
"     <b>",
"      followed by",
"     </b>",
"     oral therapy: 25 mg/kg (maximum: 500 mg) every 6 hours; total duration of therapy 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Pneumonia (MSSA) (unlabeled dosing):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Children 2 months to 5 years: Oral: 25-50 mg/kg (maximum: 2 g) every 6 hours for at least 3 weeks with gentamicin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Children &gt;5 years:  I.M., I.V.: 50 mg/kg (maximum: 2 g) every 6 hours for 10-14 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F153888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F153889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F6051361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as sodium: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 250 mg, 500 mg, 1000 mg, 2000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral, as sodium: 125 mg/5 mL (60 mL, 100 mL, 200 mL)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11218424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6051127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer with water 1 hour before or 2 hours after meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: Administer slowly over 2-4 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V. push: Administer slowly over 2-4 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V. infusion: Administer over 30-40 minutes",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F6050845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solutions: Stable in NS, LR;",
"     <b>",
"      variable stability (consult detailed reference):",
"     </b>",
"     D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Incompatible:",
"     </b>",
"     Pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Hydromorphone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Chloramphenicol, colistimethate, dimenhydrinate, lidocaine, lincomycin, procaine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Erythromycin, gentamicin, pantoprazole, polymyxin B.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Hydromorphone, kanamycin, streptomycin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F153867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bacterial infections including endocarditis, pneumonia, bone and joint infections, skin and soft-tissue infections, and sepsis that are caused by susceptible strains of  penicillinase-producing staphylococci.",
"     <b>",
"      Note:",
"     </b>",
"     Exhibits good activity against",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"     ; has activity against many streptococci, but is less active than penicillin and is generally not used in clinical practice to treat streptococcal infections.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F153899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, fever, lethargy, seizure (high doses and/or renal failure)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, black or hairy tongue, diarrhea, flatulence, nausea, oral candidiasis, pseudomembranous colitis, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, bone marrow depression, eosinophilia, granulocytopenia, hemolytic anemia, leukopenia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, myoclonus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria, interstitial nephritis, proteinuria, renal insufficiency, renal tubular damage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, laryngeal edema, laryngospasm, sneezing, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, angioedema, allergic reaction, serum sickness-like reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F153870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cloxacillin, other penicillins, cephalosporins, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F153852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Use with caution in asthmatic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Although not reported with cloxacillin, the transport of penicillins across the blood-brain barrier may be enhanced by inflamed meninges or during cardiopulmonary bypass. An increased risk of myoclonia, seizures, or reduced consciousness may be observed in these patients (particularly those with renal failure).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Penicillin use has been associated with hematologic disorders (eg, agranulocytosis, neutropenia, thrombocytopenia) believed to be a hypersensitivity phenomena. Reactions are most often reversible upon discontinuing therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; rate of elimination is reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high serum levels, particularly in the presence of renal impairment, may increase risk for seizures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neonates: May have decreased renal clearance of cloxacillin; frequent evaluation of serum levels and of clinical status for adverse effects as well as frequent dosage adjustments may be necessary in this patient population;",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F153857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cloxacillin may diminish the anticoagulant effect of Vitamin K Antagonists. Cloxacillin may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6050842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food decreases cloxacillin absorption; serum levels are reduced by ~50%. Management: Administer with water on an empty stomach 1 hour before or 2 hours after meals.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6050840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cloxacillin crosses the placenta and distributes into fetal tissue. In general, penicillins as a class are considered safe for use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F153890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F153873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken 1 hour before or 2 hours after meals with water.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F153863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for signs and symptoms of anaphylaxis during first dose; CBC with differential (prior to initiating therapy and weekly thereafter), periodic BUN, creatinine, hepatic function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F153874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ampiclox (NL);",
"     </li>",
"     <li>",
"      An Mei Lin (CL);",
"     </li>",
"     <li>",
"      Anaclosil (ES);",
"     </li>",
"     <li>",
"      Apo-Cloxi (SG);",
"     </li>",
"     <li>",
"      Bioclox (IN);",
"     </li>",
"     <li>",
"      Caxin (PH);",
"     </li>",
"     <li>",
"      Cloxacap (SG);",
"     </li>",
"     <li>",
"      Cloxam (TH);",
"     </li>",
"     <li>",
"      Cloxen (PH);",
"     </li>",
"     <li>",
"      Cloxgen (TH);",
"     </li>",
"     <li>",
"      Cloxomed (TW);",
"     </li>",
"     <li>",
"      Coclox (TH);",
"     </li>",
"     <li>",
"      Ekvacillin (NO, SE);",
"     </li>",
"     <li>",
"      Encloxil (PH);",
"     </li>",
"     <li>",
"      Eraclox (PH);",
"     </li>",
"     <li>",
"      Gaofen (CL);",
"     </li>",
"     <li>",
"      Kaifa (CL);",
"     </li>",
"     <li>",
"      Klox (IN);",
"     </li>",
"     <li>",
"      Lidoxin (HK, SG);",
"     </li>",
"     <li>",
"      Meikam (ID);",
"     </li>",
"     <li>",
"      Monoclox (MY);",
"     </li>",
"     <li>",
"      Orbenil (IL);",
"     </li>",
"     <li>",
"      Orbenin (AE, BB, BD, BF, BH, BJ, BM, BS, BZ, CI, CL, CY, EG, ET, GH, GM, GN, GR, GY, IE, IQ, IR, JM, JO, JP, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PK, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Orbenine (FR);",
"     </li>",
"     <li>",
"      Pannox (PH);",
"     </li>",
"     <li>",
"      Penstapho N (BE);",
"     </li>",
"     <li>",
"      Prostafilina A (PE);",
"     </li>",
"     <li>",
"      Prostafilina-A (CO);",
"     </li>",
"     <li>",
"      Prostaphlin-A (PH);",
"     </li>",
"     <li>",
"      Staflocil (FI);",
"     </li>",
"     <li>",
"      Syntarpen (PL);",
"     </li>",
"     <li>",
"      Vamcloxil (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F153851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F153869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: ~50%; reduced by food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely to most body fluids and bone; penetration into cells, into eye, and across normal meninges is poor; crosses placenta; enters breast milk; inflammation increases amount that crosses blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~94% (primarily albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic to active and inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 0.5-1.5 hours; prolonged with renal impairment and in neonates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Choudri SH, and The Endocarditis Care Plan Working Group, &ldquo;Consensus Guidelines for the Treatment of Infectious Endocarditis with Outpatient Parenteral Antibiotic Therapy,&rdquo;",
"      <i>",
"       Can J Infect Dis",
"      </i>",
"      , 2000, 11(Suppl D):4-10.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Enat R, Pollack S, Ben-Arieh Y, et al, &ldquo;Cholestatic Jaundice Caused by Cloxacillin: Macrophage Inhibition Factor Test in Preventing Rechallenge With Hepatotoxic Drugs,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1980, 280(6219):982-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/45/31446/abstract-text/7417768/pubmed\" id=\"7417768\" target=\"_blank\">",
"        7417768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JD, Howard JB, and Shelton S, &ldquo;Oral Antibiotic Therapy for Skeletal Infections of Children. I. Antibiotic Concentrations in Suppurative Synovial Fluid,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1978, 92(1):131-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/45/31446/abstract-text/619055/pubmed\" id=\"619055\" target=\"_blank\">",
"        619055",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nunn TR, Cheung WY, and Rollinson PD, &ldquo;A Prospective Study of Pyogenic Sepsis of the Hip in Childhood,&rdquo;",
"      <i>",
"       J Bone Joint Surg Br",
"      </i>",
"      , 2007, 89(1):100-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/45/31446/abstract-text/17259425/pubmed\" id=\"17259425\" target=\"_blank\">",
"        17259425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pichichero ME, &ldquo;Group A Beta-Hemolytic Streptococcal Infections,&rdquo;",
"      <i>",
"       Pediatr Review",
"      </i>",
"      , 1998, 19(9):291-302.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/45/31446/abstract-text/9745311/pubmed\" id=\"9745311\" target=\"_blank\">",
"        9745311",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      St. John MA and Prober CG, &ldquo;Side Effects Of Cloxacillin in Infants and Children,&rdquo;",
"      <i>",
"       Can Med Assoc J",
"      </i>",
"      , 1981, 125(5): 458-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/45/31446/abstract-text/7284928/pubmed\" id=\"7284928\" target=\"_blank\">",
"        7284928",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Westerman EL, Bradshaw MW, and Williams TW, &ldquo;Agranulocytosis During Therapy With Orally Administered Cloxacillin,&rdquo;",
"      <i>",
"       Am J Clin Pathol",
"      </i>",
"      , 1978, 69(5):559-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/45/31446/abstract-text/655134/pubmed\" id=\"655134\" target=\"_blank\">",
"        655134",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;World Health Organization Model Prescribing Information: Drugs Used in Bacterial Infections,&rdquo;  file://www.who.int/medicinedocs/en/d/Js5406e",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wright AJ, &ldquo;The Penicillins,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1999, 74(3):290-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/45/31446/abstract-text/10090000/pubmed\" id=\"10090000\" target=\"_blank\">",
"        10090000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9288 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-4838B967EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_45_31446=[""].join("\n");
var outline_f30_45_31446=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153884\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153901\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153887\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153895\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153888\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153889\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795886\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6051361\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11218424\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6051127\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6050845\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153867\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153899\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153870\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153852\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299070\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153857\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6050842\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6050840\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153890\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153873\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153863\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153874\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153851\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153869\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9288\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9288|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/37/25172?source=related_link\">",
"      Cloxacillin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_45_31447="Hepatitis B";
var content_f30_45_31447=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Hepatitis B (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/45/31447/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/45/31447/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/45/31447/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/45/31447/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/45/31447/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/45/31447/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/45/31447/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"hepatitis\" is used to describe a common form of liver injury. Hepatitis simply means \"inflammation of the liver\" (the suffix \"itis\" means inflammation and \"hepa\" means liver). Hepatitis B is a specific type of hepatitis that is caused by a virus.",
"   </p>",
"   <p>",
"    It is estimated that there are more than 300 million carriers of the hepatitis B virus in the world, with over 500,000 dying annually from hepatitis B-related liver disease.",
"   </p>",
"   <p>",
"    Fortunately, several medications are available for the treatment of chronic hepatitis B, and hepatitis B infection can be prevented by vaccination. Hepatitis B vaccines are safe and highly effective in preventing hepatitis B infection and are now given routinely to newborns and children in the United States and in many other countries. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"     \"Patient information: Adult vaccines (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More detailed information about hepatitis B is available by subscription. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23030?source=see_link\">",
"     \"Investigational treatments of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HOW DID I BECOME INFECTED WITH HEPATITIS B?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several ways to become infected with hepatitis B virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Contaminated needles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using contaminated needles can spread the hepatitis B virus. This includes tattooing, acupuncture, and ear piercing (if these procedures are performed with contaminated instruments). Sharing needles or syringes can also spread the virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual contact with someone who is infected is one of the most common ways to become infected with hepatitis B. If you are infected with hepatitis B, make sure your spouse or sex partner gets vaccinated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mother to infant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B can be passed from a mother to her baby during or shortly after delivery. Having a Cesarean delivery (also called a C-section) does not prevent the virus from spreading. Experts believe that breastfeeding is safe.",
"   </p>",
"   <p>",
"    During pregnancy, all women should have a blood test for a marker of hepatitis B virus, called hepatitis B surface antigen (HBsAg). Normally, the HBsAg should be negative.",
"   </p>",
"   <p>",
"    If the mother's HBsAg test is positive, the infant should be given a shot soon after birth (called hepatitis B immunoglobulin or HBIG). HBIG provides immediate protection to the infant, but the effect only lasts a few months. The infant should get the",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/38/10849?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    at birth, at 1 to 2 months, and at 6 months. Finishing all three doses is important for long-term protection. The infant should have a blood test for hepatitis B infection and for hepatitis B antibody at 9 to 18 months of age; if the antibody test is negative, a fourth dose of the vaccine should be given at that time. In some cases, the mother is also given a medication that reduces the amount of virus in her blood for several weeks before giving birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Close contact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B can be spread through close personal contact. This could happen if blood or other bodily fluids get into tiny cracks or breaks in your skin or in your mouth or eyes. The virus can live for a long time away from the body, meaning that it can be spread by sharing household items like toys, toothbrushes, or razors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Blood transfusion and organ transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nowadays, it is extremely rare for hepatitis B to be spread through blood transfusion or organ transplantation. Blood and organ donors are carefully screened for markers of hepatitis infection. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/12/26820?source=see_link\">",
"     \"Patient information: Blood donation and transfusion (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     In the hospital",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the hospital, hepatitis B virus can spread from one patient to another or from a patient to a doctor or nurse if there is an accidental needle stick. It is rare for a",
"    <span class=\"nowrap\">",
"     doctor/nurse",
"    </span>",
"    to pass hepatitis B to a patient. Wearing gloves, eye protection, a face mask, and washing hands can help to prevent spreading the virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HEPATITIS B SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms due to hepatitis B vary. After a person is first infected with hepatitis B, they can develop a flu-like illness that includes fever, abdominal pain, fatigue, decreased appetite, nausea, and in some cases yellowing of the skin and eyes (jaundice). In the most severe cases, liver failure can develop, which is characterized by jaundice, fluid accumulation, and confusion. However, many patients do not develop symptoms, particularly if the infection occurs in infants and children. Not having symptoms does not necessarily mean that the infection is under control. Most people with chronic hepatitis B have no symptoms until their liver disease is at a late stage. The most common early symptom is feeling tired. Everyone with chronic hepatitis B is at increased risk of developing complications, including liver scarring (called cirrhosis when the scarring is severe) and liver cancer. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44084?source=see_link\">",
"     \"Patient information: Cirrhosis (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acute hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a person is first infected with hepatitis B, they are said to have acute hepatitis. Most people with acute hepatitis B recover uneventfully.",
"   </p>",
"   <p>",
"    However, in about 5 percent of adults (1 in 20) the virus makes itself at home in the liver, where it continues to make copies of itself for many years. People who continue to harbor the virus are referred to as \"carriers\". If liver damage develops because of longstanding infection, the person is said to have chronic hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chronic hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hepatitis B develops more commonly in people who are infected with the virus at an early age (often at birth). Unfortunately, this is common in some parts of the world such as in Southeast Asia, China, and sub-Saharan Africa, where as many as 1 in 10 people have chronic hepatitis B infection.",
"   </p>",
"   <p>",
"    Many people with chronic hepatitis B have no symptoms at all; other people have symptoms of ongoing liver inflammation, such as fatigue and loss of appetite.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     HEPATITIS B DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of tests that can be used to diagnose or monitor hepatitis B infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .) Most of these tests are blood tests and include those that detect:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatitis B surface antigen (abbreviated HBsAg) &ndash; HBsAg is a protein on the surface of the hepatitis B virus. This protein shows up in the blood 1 to 10 weeks after exposure to the hepatitis B virus and before a person starts to show symptoms of the infection. In people who recover, this protein usually disappears after 4 to 6 months. Its continued presence suggests that chronic infection has developed.",
"     </li>",
"     <li>",
"      Hepatitis B surface antibody (abbreviated anti-HBs) &ndash; Anti-HBs is a protein that helps the body's immune system attack the hepatitis B virus. This protein is usually present in people who have recovered or who have been vaccinated against hepatitis B. People with this protein are usually immune to hepatitis B.",
"     </li>",
"     <li>",
"      Hepatitis B core antibody (abbreviated anti-HBc) &ndash; Anti-HBc is a protein that helps the body's immune system attack the hepatitis B virus. This protein is usually present throughout the course of infection and stays in the blood after recovery. It is not present in people who have been vaccinated against hepatitis B.",
"     </li>",
"     <li>",
"      Hepatitis B e antigen (abbreviated HBeAg) &ndash; HBeAg is a protein whose presence indicates that the hepatitis B virus is continuing to make copies of itself (replicating). Its presence usually indicates a high level of circulating virus and a high chance of transmission of infection.",
"     </li>",
"     <li>",
"      Hepatitis B e antibody (abbreviated anti-HBe) &ndash; Anti-HBe is a protein that helps the immune system attack the hepatitis B virus. Its appearance usually signifies that virus replication has slowed down, but in some variants of hepatitis B, the virus continues to replicate at a rapid rate, and high levels of virus can be found in the circulation.",
"     </li>",
"     <li>",
"      Hepatitis B DNA (abbreviated HBV DNA) &ndash; HBV DNA is the genetic material found in the hepatitis B virus. HBV DNA usually disappears from the blood after a person recovers. HBV DNA is a measure of the concentration of virus in the circulating blood. Doctors use the levels of HBV DNA to decide who is a candidate for treatment with antiviral medicines and to track how well treatment is working.",
"     </li>",
"     <li>",
"      Other tests &ndash; There are many other tests that can reflect the health of the liver but are not specific for hepatitis B. Examples include liver enzyme tests (ALT and AST), bilirubin, alkaline phosphatase, albumin, prothrombin time and platelet count.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A liver biopsy is not routinely needed to diagnose hepatitis B. A liver biopsy is used to monitor liver damage in people with chronic hepatitis, help decide if treatment is needed, and find signs of cirrhosis or liver cancer. More information about liver biopsy is available separately. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/39/4721?source=see_link\">",
"     \"Patient information: Liver biopsy (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     WILL I DEVELOP CHRONIC HEPATITIS B?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of developing chronic hepatitis B largely depends on your age at the time of infection. Chronic infection develops in about 90 percent of children who are infected at birth, in 20 to 50 percent of children who are infected between the ages of 1 and 5 years, and in less than 5 percent of people infected with hepatitis B during adulthood.",
"   </p>",
"   <p>",
"    The risk of developing complications of chronic hepatitis B depends on how rapidly the virus multiplies and how well your immune system controls the infection. Drinking alcohol, having chronic hepatitis C, or having HIV infection (the virus that causes AIDS) in addition to hepatitis B increases the chance of complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HEPATITIS B TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific treatment for acute hepatitis B is usually not needed since in about 95 percent of adults, the immune system controls the infection and gets rid of the virus within about six months.",
"   </p>",
"   <p>",
"    In people who develop chronic hepatitis, an antiviral medication might be recommended to reduce or reverse liver damage and to prevent long-term complications of hepatitis B.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several antiviral medicines are available to treat hepatitis B. Not all people with hepatitis B need immediate treatment. If you do not need to start treatment immediately, you will be monitored over time to know when hepatitis becomes more active (meaning that antiviral treatment should begin).",
"   </p>",
"   <p>",
"    Once you start treatment, you will have regular blood tests to see how well the treatment is working and to detect side effects or drug resistance. Monitoring will continue after finishing treatment to detect signs that the infection has come back.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Lamivudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/53/20309?source=see_link\">",
"     Lamivudine",
"    </a>",
"    (Epivir-HBV&reg;) is effective in decreasing hepatitis B virus activity and ongoing liver inflammation. It is safe in patients with liver failure and long-term treatment can decrease the risk of liver failure and liver cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6538?source=see_link\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/53/20309?source=see_link\">",
"     Lamivudine",
"    </a>",
"    is taken by mouth, usually at a dosage of 100",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The major problem with lamivudine is that a resistant form of hepatitis B virus (referred to as a YMDD mutant) frequently develops in people who take lamivudine long term. Other medicines are available that are less likely to cause resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Adefovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/27/30133?source=see_link\">",
"     Adefovir",
"    </a>",
"    (Hepsera&reg;) is an alternative initial choice for people who have detectable hepatitis B virus activity and ongoing liver inflammation. An advantage of adefovir compared to",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/53/20309?source=see_link\">",
"     lamivudine",
"    </a>",
"    is that resistance to adefovir is less likely to develop. In addition, adefovir can suppress lamivudine-resistant HBV. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/59/36792?source=see_link\">",
"     \"Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/27/30133?source=see_link\">",
"     Adefovir",
"    </a>",
"    is taken by mouth, at a dosage of 10",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    for at least one year. Most patients will need long-term treatment to maintain control of the hepatitis B virus. Adefovir is a weak antiviral medicine, and resistance does occur over time. Other medicines are available that are more potent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Entecavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/49/11029?source=see_link\">",
"     Entecavir",
"    </a>",
"    (Baraclude&reg;) is generally more potent than",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/53/20309?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/27/30133?source=see_link\">",
"     adefovir",
"    </a>",
"    . Resistance to entecavir is uncommon in people who have never been treated with antivirals, but occurs in up to 50 percent of people who have used lamivudine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11752?source=see_link\">",
"     \"Entecavir in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/49/11029?source=see_link\">",
"     Entecavir",
"    </a>",
"    is taken by mouth, at a dosage of 0.5 mg daily for patients who have no prior treatment and 1.0 mg daily for patients who have resistance to",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/53/20309?source=see_link\">",
"     lamivudine",
"    </a>",
"    . Most patients will need long-term treatment to maintain control of the hepatitis B virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H467255144\">",
"    <span class=\"h3\">",
"     Tenofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/4/36933?source=see_link\">",
"     Tenofovir",
"    </a>",
"    (Viread&reg;) is more potent than",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/27/30133?source=see_link\">",
"     adefovir",
"    </a>",
"    . Resistance to tenofovir is rare. Tenofovir is taken by mouth, at a dosage of 300 mg daily. Tenofovir is effective in suppressing hepatitis B virus that is resistant to",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/53/20309?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/13/20693?source=see_link\">",
"     telbivudine",
"    </a>",
"    , or",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/49/11029?source=see_link\">",
"     entecavir",
"    </a>",
"    . Tenofovir is not as effective in patients with adefovir-resistant hepatitis B. Resistance to tenofovir is uncommon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28822?source=see_link\">",
"     \"Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H467255151\">",
"    <span class=\"h3\">",
"     Telbivudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/13/20693?source=see_link\">",
"     Telbivudine",
"    </a>",
"    (Tyzeka&reg;) is more potent than",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/53/20309?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/27/30133?source=see_link\">",
"     adefovir",
"    </a>",
"    . Resistance to telbivudine is common, and hepatitis B virus that is resistant to lamivudine is also resistant to telbivudine. Telbivudine is taken by mouth at a dosage of 600 mg daily. Other medicines are available that are less likely to cause resistance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25750?source=see_link\">",
"     \"Telbivudine in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Interferon-alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon-alpha is an appropriate treatment for people with chronic hepatitis B infection who have detectable virus activity, ongoing liver inflammation, and no cirrhosis. Both conventional interferon and pegylated interferon are approved in the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14281?source=see_link\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interferon-alpha may be considered in young patients who do not have advanced liver disease and do not wish to be on long-term treatment. Interferon-alpha is not appropriate for people with cirrhosis who have liver failure or for people who have a recurrence of hepatitis after liver transplantation.",
"   </p>",
"   <p>",
"    Interferon is given for a finite duration. Pegylated interferon, a long acting interferon taken once a week, is given for one year. This is in contrast to the other hepatitis treatments, which are given by mouth for many years until a desired response is achieved. Drug resistance to interferon has not been reported.",
"   </p>",
"   <p>",
"    The disadvantages of interferon-alpha are that it must be taken by injection and it can cause many side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver transplantation may be the only option for people who have developed advanced cirrhosis. The liver transplantation process is elaborate, involving an extensive screening process to ensure that a person is a good candidate. Thus, not all patients with cirrhosis are eligible, and only those with the most advanced cirrhosis or early stage liver cancer and otherwise good medical and social conditions will be put on the transplant waiting list.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TIPS TO MAINTAIN LIVER HEALTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the majority of people with acute hepatitis B spontaneously clear the infection. Those who develop chronic infection should see a doctor with expertise in liver disease (usually a gastroenterologist or hepatologist) who can discuss treatment options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Vaccinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Everyone with chronic hepatitis B should be vaccinated against hepatitis A unless they are known to be immune. Influenza vaccination is recommended once per year, usually in the fall. Patients with liver disease should also receive standard immunizations, including a diphtheria and tetanus booster, every ten years. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"     \"Patient information: Adult vaccines (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Liver cancer screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular screening for liver cancer is also recommended, particularly for older individuals, those with cirrhosis, and patients with a family history of liver cancer. In general, this includes an ultrasound examination of the liver every six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific diet has been shown to improve the outcome in people with hepatitis B. The best advice is to eat a normal healthy and balanced diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol should be avoided since it can worsen liver damage. All types of alcoholic beverages can be harmful to the liver. People with hepatitis B can develop liver complications even with small amounts of alcohol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise is good for overall health and is encouraged, but it has no effect on the hepatitis B virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Prescription and nonprescription drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many medications are broken down by the liver. Thus, it is always best to check with a healthcare provider or pharmacist before starting a new medication. As a general rule, unless the liver is already scarred, most drugs are safe for people with hepatitis B.",
"   </p>",
"   <p>",
"    An important possible exception is",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (Tylenol&reg;); the maximum recommended dose in people with liver disease is no more than 2 grams (2000 mg or four extra strength tabs or capsules) in 24 hours. Most acetaminophen tabs or capsules contain 325 or 500 mg.",
"   </p>",
"   <p>",
"    You should avoid",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (sold as Advil, Motrin, and store brands),",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"     naproxen",
"    </a>",
"    (sold as Aleve and store brands), and",
"    <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"     aspirin",
"    </a>",
"    (sold as Bufferin, Excedrin, and store brands).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Herbal medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;No herbal treatment has been proven to improve outcomes in patients with hepatitis B, and some can cause serious liver toxicity. Herbal treatments are not recommended for anyone with hepatitis B.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sharing concerns with others infected with hepatitis B can provide support. A number of organizations are available around the world. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Where to get more information'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PREVENT INFECTION OF FAMILY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute and chronic hepatitis B are contagious. Thus, people with hepatitis B should discuss measures to reduce the risk of infecting close contacts. This includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Discuss the infection with any sexual partners and use a latex condom with every sexual encounter.",
"     </li>",
"     <li>",
"      Do not share razors, toothbrushes, or anything that has blood on it.",
"     </li>",
"     <li>",
"      Cover open sores and cuts with a bandage.",
"     </li>",
"     <li>",
"      Do not donate blood, body organs, other tissues, or sperm.",
"     </li>",
"     <li>",
"      Immediate family and household members should be tested for hepatitis B. Anyone who is at risk of hepatitis B infection should be vaccinated. (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"       \"Patient information: Adult vaccines (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Do not share any injection drug equipment (needles, syringes).",
"     </li>",
"     <li>",
"      Clean blood spills with a mixture of 1 part household bleach to 9 parts water.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hepatitis B cannot be spread by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hugging or kissing",
"     </li>",
"     <li>",
"      Sharing eating utensils or cups",
"     </li>",
"     <li>",
"      Sneezing or coughing",
"     </li>",
"     <li>",
"      Breastfeeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29278675\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29278682\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/41/26258?source=see_link\">",
"     Patient information: Hepatitis B (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/25/24979?source=see_link\">",
"     Patient information: Cirrhosis (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/22/4451?source=see_link\">",
"     Patient information: Latest medicines for hepatitis C (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/31/18931?source=see_link\">",
"     Patient information: Blood or body fluid exposure (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/45/1746?source=see_link\">",
"     Patient information: Vaccines when you have hepatitis C (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/34/25122?source=see_link\">",
"     Patient information: Liver transplant (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29278756\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=see_link\">",
"     Patient information: Adult vaccines (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/12/26820?source=see_link\">",
"     Patient information: Blood donation and transfusion (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44084?source=see_link\">",
"     Patient information: Cirrhosis (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/39/4721?source=see_link\">",
"     Patient information: Liver biopsy (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29278773\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/59/36792?source=see_link\">",
"     Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21045?source=see_link\">",
"     Characteristics of the hepatitis B virus and pathogenesis of infection",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/26/30122?source=see_link\">",
"     Clinical manifestations and natural history of hepatitis B virus infection",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6250?source=see_link\">",
"     Clinical significance and molecular characteristics of common hepatitis B virus variants",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/52/36681?source=see_link\">",
"     Clinical significance of hepatitis B virus genotypes",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12760?source=see_link\">",
"     Combination therapy for chronic hepatitis B virus infection",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=see_link\">",
"     Epidemiology, transmission, and prevention of hepatitis B virus infection",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=see_link\">",
"     Hepatitis B virus vaccination",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8569?source=see_link\">",
"     Immunizations for patients with chronic liver disease",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6538?source=see_link\">",
"     Lamivudine monotherapy for chronic hepatitis B virus infection",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23030?source=see_link\">",
"     Investigational treatments of chronic hepatitis B virus infection",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=see_link\">",
"     Overview of the management of hepatitis B and case examples",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=see_link\">",
"     Serologic diagnosis of hepatitis B virus infection",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14281?source=see_link\">",
"     Standard and pegylated interferon for chronic hepatitis B virus infection",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25750?source=see_link\">",
"     Telbivudine in the treatment of chronic hepatitis B virus infection",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=see_link\">",
"     Treatment of hepatitis B in the HIV-infected patient",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11752?source=see_link\">",
"     Entecavir in the treatment of chronic hepatitis B virus infection",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28822?source=see_link\">",
"     Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection",
"    </a>",
"    <br/>",
"    <br/>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"     www.nlm.nih.gov/medlineplus/healthtopics.html",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Centers for Disease Control",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.cdc.gov/ncidod/diseases/hepatitis/index.htm\">",
"     www.cdc.gov/ncidod/diseases/hepatitis/index.htm",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Institute of Diabetes and Digestive and Kidney Diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"     www.niddk.nih.gov",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Institute of Allergy and Infectious Diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.niaid.nih.gov/\">",
"     www.niaid.nih.gov/",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Foundation for Infectious Diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nfid.org/\">",
"     www.nfid.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Association for Study of Liver Diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.aasld.org/\">",
"     www.aasld.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Gastroenterological Association",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.gastro.org/\">",
"     www.gastro.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Liver Foundation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.liverfoundation.org/\">",
"     www.liverfoundation.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Hepatitis B Foundation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.hepb.org/\">",
"     www.hepb.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31447/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31447/abstract/1\">",
"      Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31447/abstract/2\">",
"      Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med 2009; 150:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31447/abstract/3\">",
"      European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31447/abstract/4\">",
"      Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25:472.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4575 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_45_31447=[""].join("\n");
var outline_f30_45_31447=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HOW DID I BECOME INFECTED WITH HEPATITIS B?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Contaminated needles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mother to infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Close contact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Blood transfusion and organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      In the hospital",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HEPATITIS B SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acute hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chronic hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HEPATITIS B DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      WILL I DEVELOP CHRONIC HEPATITIS B?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HEPATITIS B TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Lamivudine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Adefovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Entecavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H467255144\">",
"      - Tenofovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H467255151\">",
"      - Telbivudine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Interferon-alpha",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TIPS TO MAINTAIN LIVER HEALTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Vaccinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Liver cancer screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Prescription and nonprescription drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Herbal medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PREVENT INFECTION OF FAMILY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29278675\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29278682\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29278756\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29278773\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/59/36792?source=related_link\">",
"      Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21045?source=related_link\">",
"      Characteristics of the hepatitis B virus and pathogenesis of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/6/6250?source=related_link\">",
"      Clinical significance and molecular characteristics of common hepatitis B virus variants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/52/36681?source=related_link\">",
"      Clinical significance of hepatitis B virus genotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12760?source=related_link\">",
"      Combination therapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/30/11752?source=related_link\">",
"      Entecavir in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8569?source=related_link\">",
"      Immunizations for patients with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23030?source=related_link\">",
"      Investigational treatments of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/24/6538?source=related_link\">",
"      Lamivudine monotherapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/12/26820?source=related_link\">",
"      Patient information: Blood donation and transfusion (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/31/18931?source=related_link\">",
"      Patient information: Blood or body fluid exposure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44084?source=related_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/25/24979?source=related_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/22/4451?source=related_link\">",
"      Patient information: Latest medicines for hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?4/39/4721?source=related_link\">",
"      Patient information: Liver biopsy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/34/25122?source=related_link\">",
"      Patient information: Liver transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/45/1746?source=related_link\">",
"      Patient information: Vaccines when you have hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14281?source=related_link\">",
"      Standard and pegylated interferon for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25750?source=related_link\">",
"      Telbivudine in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28822?source=related_link\">",
"      Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_45_31448="Clinical presentation, diagnosis and management of cholesterol effusions";
var content_f30_45_31448=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation, diagnosis and management of cholesterol effusions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/45/31448/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/45/31448/contributors\">",
"     John E Heffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/45/31448/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/45/31448/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/45/31448/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/45/31448/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/45/31448/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H20969175\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholesterol pleural effusions (also called chyliform effusion or pseudochylothorax) are uncommon and are usually seen in the setting of chronic pleural inflammation or infection of greater than five years duration although shorter durations have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. By definition, they contain a high concentration of cholesterol, giving them their characteristic turbid or milky white appearance. Although similar in gross appearance, the milky appearing fluid in a chylothorax contains a high concentration of triglycerides, most commonly from disruption or obstruction of the thoracic duct.",
"   </p>",
"   <p>",
"    The diagnosis and management of cholesterol pleural effusions will be reviewed here. The etiology, clinical presentation, diagnosis, and management of chylothorax and general issues regarding the evaluation and management of pleural effusions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37192?source=see_link\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36695?source=see_link\">",
"     \"Mechanisms of pleural liquid accumulation in disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21384?source=see_link\">",
"     \"Imaging of pleural effusions in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20969867\">",
"    <span class=\"h1\">",
"     CHOLESTEROL EFFUSION VERSUS CHYLOTHORAX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholesterol effusions and chylothoraces both classically have a milky or opalescent appearance. However, their etiologies and therapy differ, making it important to distinguish them.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cholesterol effusions (also known as a pseudochylothorax or chyliform effusion) contain a high concentration of cholesterol. These effusions typically occur in patients with thickened and sometimes calcified pleural surfaces in the setting of chronic pleural inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/4,5\">",
"       4,5",
"      </a>",
"      ], although they have been reported without pleural thickening in patients with rheumatoid arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chylothoraces, by comparison, are much more common and contain a high concentration of triglycerides in the form of chylomicrons [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/1,6-8\">",
"       1,6-8",
"      </a>",
"      ]. A chylothorax occurs when lymph fluid from the thoracic duct or other lymphatic channels accumulates in the pleural space due to disruption or obstruction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37192?source=see_link\">",
"       \"Etiology, clinical presentation, and diagnosis of chylothorax\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20969434\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of cholesterol effusions is uncertain. A traditional theory proposes that lysis of erythrocytes and neutrophils in pleural fluid releases cholesterol and other lipid constituents from degenerating cell membranes; these compounds are &ldquo;trapped&rdquo; in the pleural space by the thickened pleural membranes. Eventually, these lipid constituents become concentrated and impart the milky quality to the pleural fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The occurrence of cholesterol pleural effusions in patients without pleural fibrosis, however, suggests that a more active but yet-to-be defined intrapleural process may exist that concentrates cholesterol in pleural fluid. One theory to explain this observation is that the pleural cholesterol is derived from serum lipids bound to low density lipoproteins (LDL) that accumulate in the pleural space during acute inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/9\">",
"     9",
"    </a>",
"    ]. Over time, lipoprotein binding of cholesterol shifts from LDLs to high density lipoproteins (HDL). The mechanism for this shift in lipoprotein binding is not known.",
"   </p>",
"   <p>",
"    Most likely, different mechanisms of pathogenesis exist in different clinical settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86708465\">",
"    <span class=\"h1\">",
"     ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any condition associated with a chronic pleural effusion with or without thickened pleural membranes can result in a cholesterol effusion. In the past, one of the more common causes was induced pneumothorax therapy for pulmonary tuberculosis. At present, the two most common etiologies of cholesterol effusion are tuberculous and chronic rheumatoid pleural effusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. In a systematic review of 174 reported cases, 54 percent were due to tuberculosis, 9 percent rheumatoid arthritis, and 4 percent helminth infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/1\">",
"     1",
"    </a>",
"    ]. Development of a cholesterol effusion can occur in the setting of pleural scarring from tuberculosis, despite successful treatment of the infection. In a series of 11 patients with cholesterol effusions who had previously undergone pneumothorax therapy for tuberculous, progressive pleural thickening developed over the subsequent 5 to 40 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rare causes of cholesterol effusions include pleuropulmonary paragonimiasis, hepatopulmonary echinococcosis, chronic hemothorax, chronic pneumothorax, syphilis, and lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/1,11-14\">",
"     1,11-14",
"    </a>",
"    ]. Cholesterol effusions have also been associated with alcoholism, heart failure, nephrotic syndrome, and Hodgkin disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20969441\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H228620587\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a cholesterol effusion may have no chest symptoms or may present with the insidious onset of dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/1,2,15\">",
"     1,2,15",
"    </a>",
"    ]. Chest pain is less often reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/1\">",
"     1",
"    </a>",
"    ]. Symptoms of an underlying disease (eg, weight loss, fever, night sweats, arthralgias, joint stiffness) are sometimes present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39673?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and evaluation of pulmonary tuberculosis\", section on 'Reactivation tuberculosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36967?source=see_link\">",
"     \"Paragonimiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12856?source=see_link&amp;anchor=H3576050#H3576050\">",
"     \"Tuberculous pleural effusions in HIV-negative patients\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The time course of onset of cholesterol effusion varies. Typically, patients have a history of pleural disease dating back five years or longer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/15\">",
"     15",
"    </a>",
"    ]. However, in a case series of six patients with rheumatoid arthritis, the duration of symptoms associated with the cholesterol effusions was relatively brief (median 15 months) and the pleura was normal or only minimally thickened [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/2\">",
"     2",
"    </a>",
"    ]. Rapid onset of a cholesterol effusion has also been reported in two patients with tuberculous pleurisy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/3\">",
"     3",
"    </a>",
"    ] and a patient with hepatothoracic echinococcus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with paragonimiasis are typically from an endemic area (eg, Asia, Africa, and South America) and report consuming raw shellfish [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/12,13,17\">",
"     12,13,17",
"    </a>",
"    ]. A recent onset of symptoms, such as chest pain or shortness of breath, is often reported and effusions may be bilateral. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36967?source=see_link&amp;anchor=H4#H4\">",
"     \"Paragonimiasis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H228620594\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;On physical examination, findings of decreased breath sounds and dullness to percussion may be present depending on the size and location of the effusion. In patients with rheumatoid pleurisy, joint inflammation and nodules typical of rheumatoid arthritis are often present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26969?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of lung disease associated with rheumatoid arthritis\", section on 'Pleural disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paragonimus infection can lead to painless, migratory subcutaneous swellings of various sizes or tender, firm mobile nodules containing clusters of eosinophils and immature flukes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/18\">",
"     18",
"    </a>",
"    ]. These occur most commonly on the lower abdominal wall, inguinal region, and thighs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36967?source=see_link&amp;anchor=H7#H7\">",
"     \"Paragonimiasis\", section on 'Subcutaneous infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20970224\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of patients with a suspected cholesterol effusion includes a careful history regarding prior tuberculous exposure or treatment, symptoms or signs of rheumatoid arthritis, and residence in an area endemic for Paragonimus or Echinococcus. Pleural fluid analysis is key to the diagnosis of a cholesterol effusion and other tests (eg, laboratory testing, tuberculin skin testing) are helpful in determining the cause of the cholesterol effusion. Pulmonary function tests and chest imaging assess the degree of respiratory impairment caused by the effusion, the size of the effusion radiographically, and the presence of parenchymal lung disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20970231\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The routine laboratory testing obtained in patients with a pleural effusion includes a complete blood count and differential, and also serum glucose, total protein and lactic dehydrogenase (LDH). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/7/16505?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\", section on 'Characterization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a cholesterol effusion is suspected and the patient does not have a known diagnosis of rheumatoid arthritis, a serum rheumatoid factor is usually obtained (",
"    <a class=\"graphic graphic_table graphicRef77436 \" href=\"mobipreview.htm?10/17/10524\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=see_link&amp;anchor=H205867167#H205867167\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\", section on 'Serology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with a cholesterol effusion due to paragonimiasis, peripheral blood eosinophilia is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Elevation of serum IgE is also common.",
"   </p>",
"   <p>",
"    Heart failure is listed as a rare cause of cholesterol effusion. Measurement of plasma brain natriuretic peptide (BNP) or the N-terminal fragment of BNP (NT-proBNP) is recommended when the diagnosis of heart failure is suspected, but uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of the patient with suspected heart failure\", section on 'BNP and NT-proBNP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86708549\">",
"    <span class=\"h2\">",
"     Pleural fluid analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural fluid from a diagnostic thoracentesis is sent for cell count and differential, pH, glucose, LDH, total protein, cytology, and microbiologic smear and culture. When a cholesterol effusion or chylothorax is suspected, additional tests include measurement of pleural fluid triglycerides and cholesterol, and examination of the fluid under polarized light. Lipoprotein analysis is obtained when the diagnosis remains unclear after the preceding tests. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/7/16505?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\", section on 'Pleural fluid analysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12663?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnostic thoracentesis\", section on 'Technique'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a cholesterol effusion, the pleural cholesterol level is greater than 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.17",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and the cholesterol to triglyceride ratio is &gt;1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/15,19\">",
"     15,19",
"    </a>",
"    ]. The triglyceride level is typically below 110",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.24",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    but can occasionally be higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/8\">",
"     8",
"    </a>",
"    ]. Chylomicrons, which are characteristic of chylothoraces, are absent.",
"   </p>",
"   <p>",
"    Cholesterol crystals may be visible in pleural fluid from a cholesterol effusion when viewed under polarized light and appear as rectangular plates with notched edges (",
"    <a class=\"graphic graphic_picture graphicRef73479 \" href=\"mobipreview.htm?27/35/28211\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef74417 \" href=\"mobipreview.htm?36/26/37282\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/7,20\">",
"     7,20",
"    </a>",
"    ]. Although not always present, cholesterol crystals are virtually diagnostic of a cholesterol effusion. Automatic cell counters can misinterpret the presence of a large number of cholesterol crystals as high white and red cell counts, which is corrected by performing a manual cell count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic tuberculous effusions are typically exudative with a high lymphocyte count; it is uncommon for the pleural pH or glucose to be low. The characteristics of tuberculous effusions and the role of additional diagnostic testing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12856?source=see_link&amp;anchor=H3577801#H3577801\">",
"     \"Tuberculous pleural effusions in HIV-negative patients\", section on 'Pleural fluid'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12856?source=see_link\">",
"     \"Tuberculous pleural effusions in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic rheumatoid effusions are also typically exudative; the pleural fluid glucose is usually low (&lt;29",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     1.6mmol/L)",
"    </span>",
"    and the LDH very high (eg, &gt;1000",
"    <span class=\"nowrap\">",
"     IU/L)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef77436 \" href=\"mobipreview.htm?10/17/10524\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/19\">",
"     19",
"    </a>",
"    ]. Additional details about the laboratory evaluation of rheumatoid effusions are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26969?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of lung disease associated with rheumatoid arthritis\", section on 'Thoracentesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20970245\">",
"    <span class=\"h2\">",
"     Testing for tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculin skin testing is likely to be positive in patients with a chronic tuberculous effusion, but the diagnosis of a chronic tuberculous pleural effusion depends on the presence of a positive culture for Mycobacterium tuberculosis. The sensitivity of smear and culture of pleural fluid samples for tuberculosis is low, less than 5 percent and 10 to 20 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12856?source=see_link&amp;anchor=H3577153#H3577153\">",
"     \"Tuberculous pleural effusions in HIV-negative patients\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12856?source=see_link\">",
"     \"Tuberculous pleural effusions in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pleural biopsy is typically performed when there is a suspicion for tuberculosis or the cause of the effusion remains uncertain after initial evaluation. Pleural biopsy may show caseating granulomata; cultures of pleural biopsy material have the highest likelihood of a positive culture compared with smear and culture of pleural fluid. The combination of histology and biopsy culture has close to 100 percent sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2632?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology\", section on 'Pleural biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20970252\">",
"    <span class=\"h2\">",
"     Testing for paragonimiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In areas endemic for Paragonimus, pleural fluid is examined under the microscope for ova, although this is negative in approximately 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/12,13,21-23\">",
"     12,13,21-23",
"    </a>",
"    ]. Sputum and stool tests for helminth ova are rarely positive in patients with a cholesterol effusion due to paragonimiasis. However, enzyme-linked immunoassay (ELISA) testing for Paragonimus antibodies in serum has a high sensitivity and specificity (92 and &gt;90 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/12,13,17\">",
"     12,13,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36967?source=see_link&amp;anchor=H11#H11\">",
"     \"Paragonimiasis\", section on 'Serology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20970259\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;After determining that the patient does not have communicable tuberculosis, pulmonary function tests are obtained to assess the degree of functional impairment caused by the cholesterol effusion.",
"   </p>",
"   <p>",
"    Spirometry may be normal or may show a reduction in forced vital capacity (FVC), but normal airflow. Lung volumes may also be normal or may confirm restriction with a reduction in total lung capacity.",
"   </p>",
"   <p>",
"    Diffusing capacity for carbon monoxide (DLCO) may be modestly reduced when the cholesterol effusion is large. A more substantial decrease in DLCO increases the likelihood that lung parenchymal disease (eg, rheumatoid lung) is contributing to the patient&rsquo;s dyspnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86708403\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional chest radiography typically shows a moderate sized pleural effusion that may appear loculated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21384?source=see_link&amp;anchor=H5#H5\">",
"     \"Imaging of pleural effusions in adults\", section on 'Loculated pleural effusions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contrast-enhanced chest computed tomography (CT) will often reveal thickening of the parietal and visceral pleura [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/24\">",
"     24",
"    </a>",
"    ]. Nodular or linear calcifications of the pleura may be noted. Fat-fluid and fat-calcium levels in the pleural effusion have been reported on CT views of cholesterol effusions caused by tuberculosis, rheumatoid pleurisy, and paragonimiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21384?source=see_link&amp;anchor=H6#H6\">",
"     \"Imaging of pleural effusions in adults\", section on 'Computed tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation of the size of the effusion by CT provides insight into whether dyspnea is likely related to the effusion.",
"   </p>",
"   <p>",
"    The underlying lung parenchyma is also examined with CT and may show findings suggestive of old granulomatous disease due to tuberculosis or pulmonary fibrosis consistent with rheumatoid lung. The presence of significant parenchymal lung disease (eg, rheumatoid lung) raises the possibility that lung parenchymal disease is contributing to dyspnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20969448\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial differential diagnosis of milky pleural fluid consists of chylothorax, cholesterol pleural effusion, and empyema. The history can help to distinguish between these disorders; patients with a cholesterol effusion typically have long-standing pleural disease, patients with chylothorax often have recent thoracic or neck surgery, and those with empyema often have associated cough, fever, and pleuritic chest pain. Empyema fluid is typically not opalescent and often has a fetid odor. In addition, the supernatant of an empyema clears with centrifugation, while fluid from cholesterol effusions and chylothorax does not. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37192?source=see_link&amp;anchor=H183969546#H183969546\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\", section on 'Evaluation and diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28089?source=see_link&amp;anchor=H9#H9\">",
"     \"Parapneumonic effusion and empyema in adults\", section on 'Pleural fluid analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of a cholesterol effusion is established by evaluation of pleural fluid.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microscopic examination may reveal cholesterol crystals, but the absence of this finding does not exclude the diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chemical analysis of cholesterol effusions usually demonstrates an elevated cholesterol concentration greater than 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.18",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/4\">",
"       4",
"      </a>",
"      ] and a triglyceride concentration below 110",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.24",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/19\">",
"       19",
"      </a>",
"      ]. In contrast, the triglyceride concentration is typically above this level with a chylothorax [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chylomicrons are not present in a cholesterol pleural effusion.",
"     </li>",
"     <li>",
"      Patients with cholesterol pleural effusions of obscure etiology should be thoroughly evaluated for tuberculosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12856?source=see_link&amp;anchor=H3577153#H3577153\">",
"       \"Tuberculous pleural effusions in HIV-negative patients\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients from areas endemic for paragonimiasis, additional tests usually include a peripheral eosinophil count and measurement of anti-Paragonimus antibodies (ELISA assay) in serum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/12,17\">",
"       12,17",
"      </a>",
"      ]. The peripheral eosinophil count is typically in the range of 10 to 30 percent. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36967?source=see_link&amp;anchor=H9#H9\">",
"       \"Paragonimiasis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of pleural eosinophilia in a patient with a cholesterol effusion suggests parasitic infection, but several other processes are also associated with eosinophilic, cholesterol pleural effusion, including rheumatoid pleurisy, hemothorax, and malignancy (",
"    <a class=\"graphic graphic_table graphicRef82213 \" href=\"mobipreview.htm?12/52/13132\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29527?source=see_link\">",
"     \"Pleural fluid eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20969455\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step in the management of cholesterol effusions is treatment of the underlying disease process, whether it is tuberculosis, paragonimiasis, rheumatoid pleurisy, or another treatable disease. Additional components of the management approach, such as therapeutic thoracentesis and decortication, depend on the severity of the patient&rsquo;s respiratory symptoms, degree and pattern of impairment on pulmonary function testing, and the ability of the lung to reexpand to the chest wall. In general, if the cholesterol effusion is not causing symptoms referable to the effusion, no specific drainage procedure is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86712921\">",
"    <span class=\"h2\">",
"     Treating the underlying disease process",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on analysis of case reports and case series, treatment of the underlying disease process is often successful in resolving or stabilizing cholesterol pleural effusions due to active infection or rheumatoid pleurisy, although data on the exact success rate are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of cholesterol effusions due to chronic tuberculous infection involves antituberculous medications and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12856?source=see_link&amp;anchor=H17#H17\">",
"     \"Tuberculous pleural effusions in HIV-negative patients\", section on 'Management and outcome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/47/22261?source=see_link&amp;anchor=H6#H6\">",
"     \"Tuberculous pleural effusions in HIV-infected patients\", section on 'Management and outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    According to small case series, cholesterol effusions due to rheumatoid pleurisy often stabilize with treatment of the underlying rheumatoid arthritis with disease modifying rheumatic drugs. Among six patients with rheumatoid arthritis related cholesterol effusions, a decrease in the size of the effusion was achieved in one patient with addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and an increase in the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/2\">",
"     2",
"    </a>",
"    ]. In the other patients, stability in the size of the pleural effusions was achieved in three patients treated with methotrexate and prednisone, two with methotrexate alone, and one with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Successful treatment of cholesterol effusions due to paragonimiasis has been reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (in divided doses) for two to three days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/17,26\">",
"     17,26",
"    </a>",
"    ]. Triclabendazole is not as widely available, but is generally better tolerated. The dose is 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given once or twice a day. Improvement in dyspnea and resolution of the pleural effusion occurs gradually over one to four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. Screening of family members of index cases may reveal additional cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36967?source=see_link&amp;anchor=H13#H13\">",
"     \"Paragonimiasis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86713010\">",
"    <span class=\"h2\">",
"     Therapeutic thoracentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with resting dyspnea or diminished exercise tolerance due to the mechanical effects of the cholesterol effusion, we suggest a therapeutic thoracentesis, although data in support of this is limited to case reports and case series. As an example, in a review of 53 patients, therapeutic thoracentesis was performed in 47 (88 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/1\">",
"     1",
"    </a>",
"    ]. Recurrence of pleural fluid was reported in 64 percent, some of whom responded to repeat thoracentesis. Complications of pneumothorax and empyema were reported in a small number of patients.",
"   </p>",
"   <p>",
"    During therapeutic thoracentesis in patients with a cholesterol effusion, the thickened, fibrotic pleura may restrict re-expansion of the underlying lung due to trapped lung or lung entrapment. Trapped lung is a consequence of remote pleural inflammation, while lung entrapment is a consequence of active pleural inflammation. Thus, remote pneumothorax therapy can result in trapped lung and rheumatoid pleuritis can cause lung entrapment. The key feature of both of these processes is that the underlying lung is unable to re-expand completely after thoracentesis, causing a pneumothorax or rapid reaccumulation of pleural fluid. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/62/4072?source=see_link\">",
"     \"Diagnosis and management of pleural causes of unexpandable lung\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/62/4072?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis and management of pleural causes of unexpandable lung\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment for trapped lung or lung entrapment is best performed by monitoring pleural pressures during thoracentesis to ascertain re-expansion of the underlying lung. If trapped lung exists, the pleural space elastance (the change in pleural pressure divided by the amount of pleural fluid removed) will exceed 14.5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O per liter of fluid removed. In the absence of pleural manometry, fluid removal is stopped at the point the patient feels chest discomfort.",
"    <br/>",
"   </p>",
"   <p>",
"    For patients who have improved dyspnea after therapeutic thoracentesis, we may repeat the procedure in several weeks to months, if needed for recurrent symptoms. However, if fluid recurrence occurs more rapidly, we consider decortication to avoid risks of empyema and pleurocutaneous fistula associated with repetitive thoracentesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/7,15,27\">",
"     7,15,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86713735\">",
"    <span class=\"h2\">",
"     Decortication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracotomy with decortication is a major surgical procedure in which a peel or fibrous layer is dissected off the pleural surfaces to allow re-expansion of a trapped lung. Depending on the extent of fibrosis, decortication may require a partial pleurectomy for full reexpansion to occur.&nbsp;Some surgeons will also do a pleurodesis procedure during decortication to ensure obliteration of the pleural space and prevention of the re-accumulation of a cholesterol effusion. Pleurodesis is accomplished by mechanical abrasion of the parietal pleural surface with a dry gauze sponge or by chemical pleurodesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36232?source=see_link\">",
"     \"Chemical pleurodesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30615?source=see_link\">",
"     \"Talc pleurodesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/29/37334?source=see_link&amp;anchor=H6#H6\">",
"     \"Management of refractory nonmalignant pleural effusions\", section on 'Pleurodesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thoracotomy with decortication has been reported to reduce dyspnea when performed in patients with cholesterol effusions, although the number of reported cases is very small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/5,28\">",
"     5,28",
"    </a>",
"    ]. As an example, two patients with cholesterol effusion due to prior tuberculous pleurisy had experienced only transient improvement after thoracentesis, but experienced sustained improvement after decortication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31448/abstract/5\">",
"     5",
"    </a>",
"    ]. Potential complications include prolonged chest pain from the surgery, blood loss, empyema, and bronchopleural fistula.",
"   </p>",
"   <p>",
"    For patients with persistent and disabling dyspnea due to a cholesterol effusion that has recurred rapidly despite treatment of the underlying disease and therapeutic thoracentesis, we suggest decortication when there is evidence of restrictive physiologic impairment on pulmonary function testing and the underlying lung appears able to fully reexpand. The ability of the underlying lung to expand is assessed based on factors such as the thoracic CT showing absence of underlying lung disease and a history of transient re-expansion following therapeutic thoracentesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20969824\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cholesterol pleural effusion (also known as a pseudochylothorax or chyliform effusion) typically occurs in patients with thickened and sometimes calcified pleural surfaces in the setting of a chronic pleural effusion, usually of five years duration or longer. The fluid is characteristically milky or opalescent in appearance. Cholesterol effusions can occur, however, in the absence of pleural thickening. (See",
"      <a class=\"local\" href=\"#H20969867\">",
"       'Cholesterol effusion versus chylothorax'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The exact pathogenesis of cholesterol effusions is uncertain, but they are most commonly seen in patients with long-standing tuberculosis (infection or pneumothorax therapy), rheumatoid pleurisy, or as a complication of helminth infection. (See",
"      <a class=\"local\" href=\"#H20969434\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H86708465\">",
"       'Etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chemical analysis of cholesterol effusions usually demonstrates an elevated cholesterol concentration greater than 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.18",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and a triglyceride concentration below 110",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.24",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      In contrast, chylothoraces are characterized by a triglyceride concentration above this level. Cholesterol crystals are diagnostic if present (",
"      <a class=\"graphic graphic_picture graphicRef73479 \" href=\"mobipreview.htm?27/35/28211\">",
"       picture 1",
"      </a>",
"      ); chylomicrons, which are associated with chylothoraces, are absent. (See",
"      <a class=\"local\" href=\"#H20969448\">",
"       'Diagnosis and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causative underlying disease is sought based on history (eg, tuberculous exposure, arthritis, helminth endemic area), physical exam, tuberculin skin testing, laboratory testing (eg, peripheral eosinophilia, rheumatoid factor), microbiologic cultures of pleural fluid, and pleural fluid cytology (",
"      <a class=\"graphic graphic_table graphicRef77436 \" href=\"mobipreview.htm?10/17/10524\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20970224\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial step in the management of cholesterol effusions is treatment of the underlying disease process, whether it is tuberculosis, paragonimiasis, rheumatoid pleurisy, or other treatable disease. The medical treatment of these diseases is discussed separately. (See",
"      <a class=\"local\" href=\"#H20969455\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12856?source=see_link&amp;anchor=H17#H17\">",
"       \"Tuberculous pleural effusions in HIV-negative patients\", section on 'Management and outcome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36967?source=see_link&amp;anchor=H13#H13\">",
"       \"Paragonimiasis\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link\">",
"       \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/58/27561?source=see_link\">",
"       \"Treatment of echinococcosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients without dyspnea referable to the cholesterol effusion, we suggest avoidance of drainage procedures beyond a diagnostic thoracentesis, while waiting for a response to treatment of the underlying disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20969455\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with resting dyspnea or diminished exercise tolerance due to the mechanical effects of the cholesterol effusion, we recommend a therapeutic thoracentesis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Patients with a cholesterol effusion are at increased risk of having lung entrapment or a trapped lung, so we typically monitor symptoms and pleural pressures during therapeutic thoracentesis to ascertain re-expansion of the underlying lung. Fluid removal is stopped when the patient experiences chest discomfort or the pleural elastance exceeds 14.5 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O per liter of fluid removed. (See",
"      <a class=\"local\" href=\"#H86713010\">",
"       'Therapeutic thoracentesis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/62/4072?source=see_link&amp;anchor=H7#H7\">",
"       \"Diagnosis and management of pleural causes of unexpandable lung\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Potential surgical candidates for decortication include those who would be able to tolerate surgery and whose pulmonary function testing and high resolution CT suggest little underlying interstitial lung disease. Surgical candidates who have persistent disabling dyspnea despite treatment of the underlying disease and therapeutic thoracentesis should proceed to decortication. For other surgical candidates who require frequent thoracentesis for control of symptoms, we suggest decortication (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternatives include continued intermittent thoracentesis or placement of an indwelling pleural catheter. (See",
"      <a class=\"local\" href=\"#H86713735\">",
"       'Decortication'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/1\">",
"      Garcia-Zamalloa A, Ruiz-Irastorza G, Aguayo FJ, Gurrutxaga N. Pseudochylothorax. Report of 2 cases and review of the literature. Medicine (Baltimore) 1999; 78:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/2\">",
"      Wrightson JM, Stanton AE, Maskell NA, et al. Pseudochylothorax without pleural thickening: time to reconsider pathogenesis? Chest 2009; 136:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/3\">",
"      Nogueras C, Monteagudo M, Vila M, et al. Recent-onset tuberculous pleurisy presenting as pseudochylothorax. Am J Med 2002; 113:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/4\">",
"      COE JE, AIKAWA JK. Cholesterol pleural effusion. Report of 2 cases studied with isotopic techniques and review of the world literature. Arch Intern Med 1961; 108:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/5\">",
"      Hillerdal G. Chyliform (cholesterol) pleural effusion. Chest 1985; 88:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/6\">",
"      Roy, PH, Carr, DT, Payne, WS. The problem of chylothorax. Mayo Clin Proc 1967; 42:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/7\">",
"      Hillerdal G. Chylothorax and pseudochylothorax. Eur Respir J 1997; 10:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/8\">",
"      Agrawal V, Sahn SA. Lipid pleural effusions. Am J Med Sci 2008; 335:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/9\">",
"      Hamm H, Pfalzer B, Fabel H. Lipoprotein analysis in a chyliform pleural effusion: implications for pathogenesis and diagnosis. Respiration 1991; 58:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/10\">",
"      Balbir-Gurman A, Yigla M, Nahir AM, Braun-Moscovici Y. Rheumatoid pleural effusion. Semin Arthritis Rheum 2006; 35:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/11\">",
"      Prakash, UBS. Chylothorax and pseudochylothorax. Eur Respir Mon 2002; 7:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/12\">",
"      Thewjitcharoen Y, Poopitaya S. Paragonimiasis presenting with unilateral pseudochylothorax: case report and literature review. Scand J Infect Dis 2006; 38:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/13\">",
"      Inoue Y, Kawaguchi T, Yoshida A, et al. Paragonimiasis miyazakii associated with bilateral pseudochylothorax. Intern Med 2000; 39:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/14\">",
"      Ryu JH, Tomassetti S, Maldonado F. Update on uncommon pleural effusions. Respirology 2011; 16:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/15\">",
"      Huggins JT. Chylothorax and cholesterol pleural effusion. Semin Respir Crit Care Med 2010; 31:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/16\">",
"      Carel RS, Schey G, Bruderman I. Chyliform pleural effusion. An unusual manifestation of hepatothoracic echinococcus cysts. Chest 1975; 68:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/17\">",
"      Jujo T, Suda A, Yahaba M, et al. [Paragonimiasis Westermani associated with pseudochylothorax]. Nihon Kokyuki Gakkai Zasshi 2009; 47:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/18\">",
"      Dainichi T, Nakahara T, Moroi Y, et al. A case of cutaneous paragonimiasis with pleural effusion. Int J Dermatol 2003; 42:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/19\">",
"      Hooper C, Lee YC, Maskell N, BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2:ii4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/20\">",
"      Shen PU, Blair JL. Cholesterol crystals causing falsely elevated automated cell count. Am J Clin Pathol 2006; 125:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/21\">",
"      Minh VD, Engle P, Greenwood JR, et al. Pleural paragonimiasis in a Southeast Asia refugee. Am Rev Respir Dis 1981; 124:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/22\">",
"      Hiratsuka T, Kodama T, Nakamura F. [Paragonimiasis westermani with repeated pleural effusion and diagnosed by detecting parasite eggs in pleural effusion]. Nihon Kokyuki Gakkai Zasshi 2007; 45:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/23\">",
"      Johnson JR, Falk A, Iber C, Davies S. Paragonimiasis in the United States. A report of nine cases in Hmong immigrants. Chest 1982; 82:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/24\">",
"      Song JW, Im JG, Goo JM, et al. Pseudochylous pleural effusion with fat-fluid levels: report of six cases. Radiology 2000; 216:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/25\">",
"      Staats BA, Ellefson RD, Budahn LL, et al. The lipoprotein profile of chylous and nonchylous pleural effusions. Mayo Clin Proc 1980; 55:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/26\">",
"      Tanijiri T, Yonezu S, Torii Y, et al. [Paragonimus westermani infection confirmed by the detection of Paragonimus ova in the sputum with bilateral pleural effusion]. Nihon Kokyuki Gakkai Zasshi 2009; 47:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/27\">",
"      Sassoon CS, Light RW. Chylothorax and pseudochylothorax. Clin Chest Med 1985; 6:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31448/abstract/28\">",
"      GOLDMAN A, BURFORD TH. Cholesterol pleural effusion: A report of 3 cases with a cure by decortication. Dis Chest 1950; 18:586.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16317 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-0D0D3C1A28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_45_31448=[""].join("\n");
var outline_f30_45_31448=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20969824\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20969175\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20969867\">",
"      CHOLESTEROL EFFUSION VERSUS CHYLOTHORAX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20969434\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86708465\">",
"      ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20969441\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H228620587\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H228620594\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20970224\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20970231\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86708549\">",
"      Pleural fluid analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20970245\">",
"      Testing for tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20970252\">",
"      Testing for paragonimiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20970259\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86708403\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20969448\">",
"      DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20969455\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86712921\">",
"      Treating the underlying disease process",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86713010\">",
"      Therapeutic thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86713735\">",
"      Decortication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20969824\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/16317\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/16317|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/35/28211\" title=\"picture 1\">",
"      Cholesterol crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/26/37282\" title=\"picture 2\">",
"      Crystals in synovial fluid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/16317|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/17/10524\" title=\"table 1\">",
"      Rheumatoid pleural effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/52/13132\" title=\"table 2\">",
"      Causes pleural eosinophilia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36232?source=related_link\">",
"      Chemical pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39673?source=related_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/62/4072?source=related_link\">",
"      Diagnosis and management of pleural causes of unexpandable lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2632?source=related_link\">",
"      Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12663?source=related_link\">",
"      Diagnostic thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37192?source=related_link\">",
"      Etiology, clinical presentation, and diagnosis of chylothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21384?source=related_link\">",
"      Imaging of pleural effusions in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=related_link\">",
"      Initial treatment of moderately to severely active rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/29/37334?source=related_link\">",
"      Management of refractory nonmalignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36695?source=related_link\">",
"      Mechanisms of pleural liquid accumulation in disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26969?source=related_link\">",
"      Overview of lung disease associated with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36967?source=related_link\">",
"      Paragonimiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28089?source=related_link\">",
"      Parapneumonic effusion and empyema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29527?source=related_link\">",
"      Pleural fluid eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30615?source=related_link\">",
"      Talc pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/58/27561?source=related_link\">",
"      Treatment of echinococcosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/47/22261?source=related_link\">",
"      Tuberculous pleural effusions in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12856?source=related_link\">",
"      Tuberculous pleural effusions in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_45_31449="Factitial dermatitis";
var content_f30_45_31449=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76670%7EDERM%2F55697%7EDERM%2F67422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76670%7EDERM%2F55697%7EDERM%2F67422&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Factitial ulcerations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulcerations created by the patient. Note their geometric appearance. The patient had a severe psychiatric disorder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Factitial dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Self-induced purpuric lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Factitial ulcerations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Self inflicted ulcerations. The lesions have a geometric shape and are at the same stage of development.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_45_31449=[""].join("\n");
var outline_f30_45_31449=null;
var title_f30_45_31450="Surgical and endovascular repair of popliteal artery aneurysm";
var content_f30_45_31450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical and endovascular repair of popliteal artery aneurysm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/45/31450/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/45/31450/contributors\">",
"     Amy B Reed, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/45/31450/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/45/31450/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/45/31450/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/45/31450/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/45/31450/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/45/31450/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1231031427\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Popliteal artery aneurysm presents in a variety of ways. Many patients are asymptomatic, while others have symptoms referable to the aneurysm such as pain with ambulation (claudication) or acute limb ischemia due to aneurysm thrombosis or distal embolization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. When popliteal aneurysm repair is indicated, an open surgical or endovascular approach can be used. The choice of repair depends upon the clinical presentation, anatomic factors, and patient comorbidities.",
"   </p>",
"   <p>",
"    The approach to popliteal artery aneurysm repair, perioperative care, complications of repair, and surgical outcomes will be reviewed here. The diagnosis and nonsurgical management of popliteal artery aneurysm are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link\">",
"     \"Popliteal artery aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031434\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical or endovascular repair for popliteal aneurysms is indicated under the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic (eg acute limb ischemia, disabling claudication) popliteal aneurysm of any size",
"     </li>",
"     <li>",
"      Selected asymptomatic popliteal aneurysm (patent) depending upon size and presence of thrombus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These indications are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link&amp;anchor=H1231035358#H1231035358\">",
"     \"Popliteal artery aneurysm\", section on 'Symptomatic patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link&amp;anchor=H1231035351#H1231035351\">",
"     \"Popliteal artery aneurysm\", section on 'Asymptomatic patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031441\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications (absolute or relative) to repair of popliteal artery aneurysm include asymptomatic patients with completely thrombosed popliteal artery aneurysm, nonambulatory patients, and those with acutely thrombosed aneurysms with persistently poor runoff in spite of thrombolysis.",
"   </p>",
"   <p>",
"    Asymptomatic patients with a completely thrombosed popliteal aneurysm are",
"    <strong>",
"     not",
"    </strong>",
"    repaired, regardless of the diameter of the popliteal artery aneurysm. These patients can be managed in a manner similar to patients with lower extremity peripheral artery disease if symptoms (eg, claudication) develop, with surgical bypass reserved only for disabling symptoms or critical limb ischemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link&amp;anchor=H1231035351#H1231035351\">",
"     \"Popliteal artery aneurysm\", section on 'Asymptomatic patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link&amp;anchor=H1314527#H1314527\">",
"     \"Popliteal artery aneurysm\", section on 'Chronic ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most patients with appropriate indications for repair are candidates for open or endovascular repair, patients who are nonambulatory and those with prohibitive risks for intervention should be treated conservatively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link&amp;anchor=H20038379#H20038379\">",
"     \"Popliteal artery aneurysm\", section on 'Indications for repair'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with acutely thrombosed popliteal aneurysms who have persistently poor (or no) runoff through the tibial vessels in spite of thrombolysis (preoperative or intraoperative) may be poor candidates for popliteal artery repair. In one retrospective review, poor runoff (as measured by runoff score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/4\">",
"     4",
"    </a>",
"    ]) was one of only two variables associated with loss of graft patency; ongoing smoking was the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/5\">",
"     5",
"    </a>",
"    ]. However, in this study, nearly half of the grafts used were synthetic. In another review in which only vein grafts were used, the outcome did not correlate with runoff anatomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, in patients with acutely thrombosed popliteal aneurysms, poor runoff following thrombolysis may be a relative contraindication to popliteal artery aneurysm repair if a suitable vein conduit is not available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link&amp;anchor=H16064863#H16064863\">",
"     \"Popliteal artery aneurysm\", section on 'Role of antithrombotic therapy and thrombolysis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1231031621\">",
"     'Outcomes'",
"    </a>",
"    below.),",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031448\">",
"    <span class=\"h1\">",
"     ANATOMY OF THE POPLITEAL FOSSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The popliteal fossa is a diamond-shaped space located posterior to the knee joint. The superior and inferior margins are defined by the supracondylar line of the femur and soleal line of the tibia, respectively. From a posterior view (",
"    <a class=\"graphic graphic_figure graphicRef62362 \" href=\"mobipreview.htm?18/13/18646\">",
"     figure 1",
"    </a>",
"    ), the space is bounded above the knee by the biceps femoris tendon which inserts laterally, and semimembranous tendon which inserts medially. Below the knee, the medial and lateral margins are formed by the insertions of the medial and lateral heads of the gastrocnemius muscle.",
"   </p>",
"   <p>",
"    The popliteal fossa contains the popliteal artery, popliteal veins, and tibial nerve. The popliteal artery is the continuation of the superficial femoral artery. Anatomic landmarks demarcating the popliteal artery include the tendinous insertion of the adductor magnus muscle in the distal femur superiorly, and the bifurcation of the popliteal artery into the anterior tibial artery and tibioperoneal trunk at the level of the tibial tuberosity inferiorly. Anatomic variations of the distal popliteal artery include a high origin of the anterior tibial artery, trifurcation of the vessel into the anterior tibial, peroneal, and posterior tibial arteries (ie, no tibioperoneal trunk), and a hypoplastic or aplastic posterior tibial artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Collateral flow around the knee is critical in maintaining lower extremity perfusion when a popliteal aneurysm thromboses (",
"    <a class=\"graphic graphic_figure graphicRef72956 \" href=\"mobipreview.htm?25/60/26566\">",
"     figure 2",
"    </a>",
"    ). Collateral pathways are provided by the superior and inferior genicular (medial and lateral), anterior recurrent tibial, and descending genicular arteries.",
"   </p>",
"   <p>",
"    The popliteal vein is typically paired, traveling adjacent the popliteal artery with numerous interconnections (venae comitantes); one of the veins usually predominates in size. The popliteal vein originates at the confluence of the anterior and posterior tibial veins; the peroneal veins empty into it more superiorly. The popliteal vein becomes the femoral vein at the adductor canal.",
"   </p>",
"   <p>",
"    The tibial nerve is derived from the sciatic nerve. In the popliteal fossa, the tibial nerve gives off muscular branches (ie, gastrocnemius, popliteus, soleus, plantaris), and a sensory branch (ie, soleal nerve) that innervates the lateral aspect of the foot. The tibial nerve traverses distally in the leg along the surface of the soleus muscle supplying the muscles that plantar flex the foot.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031455\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to open surgical or endovascular repair of the popliteal artery, the patient's clinical condition, medical comorbidities and vascular anatomy, including the presence of other large vessel aneurysms, are evaluated. These factors influence the timing of repair and the choice between open surgical or endovascular repair of the popliteal aneurysm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H604915778\">",
"    <span class=\"h2\">",
"     Clinical assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Popliteal aneurysm is often asymptomatic, but many patients have symptoms referable to the aneurysm, with symptoms ranging from pain with walking (ie, intermittent claudication) to symptoms of acute limb ischemia due to acute aneurysm thrombosis, or distal embolization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link&amp;anchor=H1231035344#H1231035344\">",
"     \"Popliteal artery aneurysm\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13368?source=see_link&amp;anchor=H6#H6\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\", section on 'Clinical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymptomatic patients and those with viable limbs that are not threatened (",
"    <a class=\"graphic graphic_table graphicRef75112 \" href=\"mobipreview.htm?40/47/41723\">",
"     table 1",
"    </a>",
"    ) can undergo outpatient preoperative evaluation and repair. For patients who present acutely with a threatened extremity, urgent or emergent inpatient evaluation and repair are undertaken. In patients with acute thrombosis, an intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    infusion should be initiated to limit the extension of thrombus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link&amp;anchor=H16064863#H16064863\">",
"     \"Popliteal artery aneurysm\", section on 'Role of antithrombotic therapy and thrombolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limb salvage rates following repair of popliteal artery aneurysm (open surgical or endovascular) correlate with an increasing number of patent tibial outflow vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ]. To improve outflow, thrombolytic therapy (catheter-directed or intraoperative) or thromboembolectomy are routinely performed. Catheter-directed thrombolysis is less appropriate for immediately-threatened extremities because length of time needed to dissolve the clot is usually prolonged (12 to 24 hours). (See",
"    <a class=\"local\" href=\"#H542106921\">",
"     'Open versus endovascular repair'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H604915890\">",
"    <span class=\"h2\">",
"     Anatomic assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging the patient's vascular anatomy is necessary prior to repair. Arterial imaging with computed tomography (CT), magnetic resonance (MR) angiography, or invasive arteriography assesses the suitability for endovascular repair, evaluates proximal and distal arterial patency and may identify coexisting aneurysm. Although duplex ultrasound may identify the presence of an aneurysm, it does not show sufficient detail to plan a repair but is essential for mapping the venous system to identify suitable veins to serve as a bypass conduit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=see_link&amp;anchor=H58544718#H58544718\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Ultrasound'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=see_link&amp;anchor=H58544732#H58544732\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Other imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601500443\">",
"    <span class=\"h3\">",
"     Suitability for endovascular repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tortuosity and extent of aneurysm, and presence of adequate stent-graft landing zones should be carefully evaluated. At least 1 cm of normal artery should be available proximal and distal to the aneurysm to obtain adequate stent-graft fixation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1231031579\">",
"     'Endovascular aneurysm repair'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The aneurysm may be limited to the popliteal fossa or extend proximally to the distal superficial femoral artery or distally to popliteal artery bifurcation. Focal aneurysms more typically have normal appearing proximal and distal popliteal artery segments, but popliteal artery aneurysms are frequently associated with diffuse arteriomegaly. Focal aneurysms are amenable to a short bypass or placement of a single stent-graft. Angulation may be present (most commonly at the adductor canal) if the aneurysm extends proximally into the superficial femoral artery. Although mild angulation may straighten with a stent, severe angulation (&gt;45 degrees) is likely to cause future kinking of the stent and open surgical repair may be more appropriate.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H601500472\">",
"    <span class=\"h3\">",
"     Proximal and distal circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low flow due to proximal stenosis or occlusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreased outflow from a",
"    <span class=\"nowrap\">",
"     stenotic/thrombosed",
"    </span>",
"    popliteal artery or occluded tibial vessels decreases patency rates of open surgical and endovascular repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/9,11-13\">",
"     9,11-13",
"    </a>",
"    ]. Restoration of arterial inflow with stenting or bypass",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    restoration of arterial outflow with",
"    <span class=\"nowrap\">",
"     thrombectomy/thrombolysis",
"    </span>",
"    should be performed prior to, or at the same setting as, popliteal aneurysm repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atherosclerotic peripheral artery disease is present in a significant proportion of patients with popliteal artery aneurysm and should be managed concomitant with popliteal artery aneurysm to improve the outcomes of repair. In one retrospective review, 40 percent of patients had severe atherosclerosis of the femoral artery. Atherosclerosis-related occlusion of the superficial femoral artery was present in 17 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tibial vessel occlusion in patients with popliteal artery aneurysm is most likely due to thromboembolism. Thrombolytic therapy (catheter-directed or direct intraoperative) may restore patency of the anterior tibial, posterior tibial, or peroneal arteries in patients presenting with acute ischemia, thus improving the likelihood of a successful popliteal artery aneurysm repair. Patients with acutely thrombosed popliteal artery aneurysms who have poor runoff in spite of thrombolysis may be poor candidates for popliteal artery aneurysm repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link&amp;anchor=H16064863#H16064863\">",
"     \"Popliteal artery aneurysm\", section on 'Role of antithrombotic therapy and thrombolysis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1231031441\">",
"     'Contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H604916299\">",
"    <span class=\"h3\">",
"     Coexistent aneurysms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Popliteal aneurysm is a marker for a large artery aneurysm diathesis. An estimated 75 percent of patients with a popliteal aneurysm will have another aneurysm at a separate site (contralateral popliteal artery, femoral arteries, abdominal aorta, iliac arteries) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link&amp;anchor=H1231035388#H1231035388\">",
"     \"Popliteal artery aneurysm\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of other aneurysms (aortic, iliac, or femoral) influences the timing and nature of the popliteal aneurysm repair. Generally, for asymptomatic patients, aneurysms proximal to the popliteal aneurysm should be managed first, if indicated, as these have a potential to embolize distally and may occlude the popliteal bypass or stent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H604916154\">",
"    <span class=\"h3\">",
"     Availability of conduit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term patency rates are higher when autogenous vein rather than prosthetic graft is used for lower extremity bypass below the knee [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/5,6,15\">",
"     5,6,15",
"    </a>",
"    ], and thus, the availability of vein may determine the approach to popliteal aneurysm repair. The diameter, length, and patency of the great saphenous vein ipsilateral and contralateral to the popliteal aneurysm should be evaluated. The ipsilateral saphenous vein may be preferred in patients with bilateral aneurysms and in those with more extensive popliteal aneurysms (ie, requiring a long bypass). The femoral vein is an acceptable conduit if great saphenous vein is not available bilaterally and the patient is not a candidate for endovascular repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031484\">",
"    <span class=\"h2\">",
"     Medical risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors for popliteal artery aneurysm are similar to those of other major vascular aneurysms (ie, abdominal aortic, iliac, and femoral aneurysms) and include smoking, hypertension, hyperlipidemia, cerebrovascular disease, and coronary heart disease, among others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/3\">",
"     3",
"    </a>",
"    ]. However, in contrast to atherosclerotic occlusive disease, diabetes mellitus is associated with a decreased risk for aneurysmal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link&amp;anchor=H1231035337#H1231035337\">",
"     \"Popliteal artery aneurysm\", section on 'Risk factors'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Because of these associations, a complete medical history with particular attention to risk factors for cardiovascular disease should be obtained, since comorbidities may impact the choice of repair. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link\">",
"     \"Management of cardiac risk for noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to elective repair, the patient should be referred to a smoking cessation program. Active smoking at the time of surgery is associated with an increased risk for pulmonary complications and is an independent risk factor for bypass graft failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link&amp;anchor=H1231035395#H1231035395\">",
"     \"Popliteal artery aneurysm\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=see_link&amp;anchor=H4#H4\">",
"     \"Strategies to reduce postoperative pulmonary complications\", section on 'Smoking cessation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542106921\">",
"    <span class=\"h1\">",
"     OPEN VERSUS ENDOVASCULAR REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of popliteal artery aneurysm repair is to eliminate the aneurysm from the circulation and maintain perfusion to the extremity. Open surgical bypass and endovascular stent-grafting each accomplish these goals. Whether an open surgical or endovascular approach is preferred is the subject of much debate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/16\">",
"     16",
"    </a>",
"    ]. Limited data are available comparing popliteal artery aneurysm repair techniques, and major society guidelines provide no guidance in choosing between open surgical versus endovascular repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. We advocate an individualized approach taking into account the clinical presentation (elective versus emergent), the degree of limb ischemia, the patient&rsquo;s medical comorbidities, and their vascular anatomy (suitability for endograft, status of the",
"    <span class=\"nowrap\">",
"     proximal/distal",
"    </span>",
"    circulation, coexistent aneurysm, availability of vein conduit).",
"   </p>",
"   <p>",
"    The benefit of endovascular stent-grafting may be the greatest in patients with indications for elective repair who have a high perioperative risk for surgery. We suggest endovascular repair in these patients provided the popliteal segment is suitable for endograft placement (see",
"    <a class=\"local\" href=\"#H601500443\">",
"     'Suitability for endovascular repair'",
"    </a>",
"    above). Compared with endovascular repair, open repair is associated with increased mortality, particularly in patients with medical comorbidities, although some have argued that the outcomes of studies comparing open and endovascular repair may be biased since open repair of popliteal artery aneurysm is more commonly used for managing patients with acute popliteal aneurysm thrombosis. Nevertheless, we feel that avoiding the risks associated with anesthesia and potentially the need for transfusion in high-risk patients is highly desirable. (See",
"    <a class=\"local\" href=\"#H1231031621\">",
"     'Outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Whether patients with indications for elective repair who are",
"    <strong>",
"     not",
"    </strong>",
"    at high risk for open surgery should undergo open surgical or endovascular repair is more controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. For these patients, we suggest open surgical repair, provided the patient has adequate vein conduit. If adequate vein is not available, an endovascular approach is an acceptable alternative. Open surgical repair is the accepted standard and is a durable procedure that has been shown in retrospective studies to be associated with low perioperative morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/8,16,19,22\">",
"     8,16,19,22",
"    </a>",
"    ]. Early graft failure is uncommon and long-term rates for limb loss are low. A systematic review identified one randomized trial and two retrospective reviews comparing open surgical and endovascular repair of popliteal aneurysm repair (not acutely thrombosed) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/19\">",
"     19",
"    </a>",
"    ]. Although there were no significant differences in the overall patency of popliteal bypass grafts compared with endovascular stent-grafts, endovascular repair had a significantly increased risk of early (30-day) reintervention (OR 18.8, 95% CI 1.4-245.9), and a trend toward early (30-day) graft thrombosis. The main advantage of endovascular repair was a shorter length of hospital stay (weighted mean difference -3.9 days, 95% CI -4.3 - -3.4). An update of the randomized trial included in the metaanalysis above assessed longer-term outcomes in 27 open and 21 endovascular repairs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/23\">",
"     23",
"    </a>",
"    ]. Primary patency rates in patients undergoing open popliteal aneurysm repair compared with endovascular repair were not significantly different at 12 or 72 months follow-up. Secondary patency rates at 72 months were 88 and 86 percent for open and endovascular repair, respectively.",
"   </p>",
"   <p>",
"    Other factors need to be taken into consideration in patients undergoing popliteal artery aneurysm repair for emergent indications (acute thrombosis, rupture). Thrombolytic therapy is appropriate for thrombosed popliteal artery aneurysms causing acute limb ischemia to improve outflow, provided the limb is not immediately threatened. Patients with an immediately-threatened limb are treated with an open surgical approach that includes thromboembolectomy and intraoperative infusion of lytic agents rather than using a percutaneous method of thrombolysis due to the prolonged time needed to lyse a heavy burden of thrombus that could further compromise the extremity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/9,24,25\">",
"     9,24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link&amp;anchor=H16064863#H16064863\">",
"     \"Popliteal artery aneurysm\", section on 'Role of antithrombotic therapy and thrombolysis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1231031621\">",
"     'Outcomes'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13368?source=see_link&amp;anchor=H506060463#H506060463\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\", section on 'Threatened extremity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients for whom adequate distal runoff (two or three vessel runoff) is restored following percutaneous thrombolytic therapy, a decision for open versus endovascular repair can be made based upon an assessment of perioperative surgical risk and anatomic factors, as discussed above for elective repair. If distal runoff is not adequately restored following thrombolysis, we suggest an aggressive attempt at surgical revascularization provided that a distal target for revascularization is identified and the patient has adequate vein conduit.",
"   </p>",
"   <p>",
"    Ruptured popliteal artery aneurysms are uncommon (3 percent in one study). Ruptured popliteal aneurysms may be best managed using a hybrid approach, with endovascular techniques for initial control of hemorrhage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    repair of the vessel, and open techniques to manage the hematoma, as needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, ruptured popliteal aneurysms may be associated with infection, which necessitates complete excision of the aneurysm and ideally autogenous reconstruction, although an endovascular approach has also been used for high-risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/17/35098?source=see_link&amp;anchor=H8476403#H8476403\">",
"     \"Overview of infected (mycotic) arterial aneurysm\", section on 'Lower extremity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031506\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031514\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with acute thrombotic occlusion or distal embolization, systemic anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombolytic agents will have been instituted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13368?source=see_link\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link&amp;anchor=H16064863#H16064863\">",
"     \"Popliteal artery aneurysm\", section on 'Role of antithrombotic therapy and thrombolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once a decision to proceed to open surgery to repair popliteal artery aneurysm has been made, the thrombolytic agent should be discontinued to minimize intraoperative bleeding. Systemic anticoagulation should be resumed after the thrombolytic agent has been discontinued, and maintained up to the time of the operation to decrease the risk for re-thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031521\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic prophylaxis is recommended within one hour of the skin incision for patients undergoing vascular surgical procedures that involve a groin incision or the use of prosthetic material. Antibiotic choices are given in the tables (",
"    <a class=\"graphic graphic_table graphicRef87206 \" href=\"mobipreview.htm?34/1/34844\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63103 \" href=\"mobipreview.htm?33/9/33950\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031528\">",
"    <span class=\"h2\">",
"     DVT prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing major vascular procedures are at moderate to high risk for developing deep vein thrombosis (older age, bed rest postoperatively, major surgery &gt;45 minutes) (",
"    <a class=\"graphic graphic_table graphicRef83739 \" href=\"mobipreview.htm?22/50/23341\">",
"     table 4",
"    </a>",
"    ) and should receive prophylaxis if not already receiving systemic anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who present with DVT as a manifestation of popliteal aneurysm, we treat the DVT according to standard protocols and delay elective open repair. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031535\">",
"    <span class=\"h2\">",
"     Patient counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the risk of procedure-related complications are overall low, patients undergoing elective popliteal artery aneurysm repair are counseled regarding their individual risk for",
"    <span class=\"nowrap\">",
"     morbidity/mortality",
"    </span>",
"    compared with the benefits of popliteal artery aneurysm repair (ie, lowered risk of future limb-threatening ischemia). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link\">",
"     \"Popliteal artery aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients undergoing endovascular repair, the most common complications are related to the percutaneous access site, but the possibility of stent-graft thrombosis (early or late), or device-related complications such as stent migration or kinking requiring reintervention or conversion to open surgical bypass should be discussed. (See",
"    <a class=\"local\" href=\"#H1231031593\">",
"     'Stent-graft complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For open surgery, complications include bleeding requiring transfusion, infection, and graft thrombosis. The potential need for further surgery to revise or manage graft infection or thrombosis should be conveyed. Graft thrombosis and graft infection increase the risk for future amputation. (See",
"    <a class=\"local\" href=\"#H1231031572\">",
"     'Surgical complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients requiring emergent popliteal aneurysm repair due to acute popliteal aneurysm thrombosis have a greater risk for complications, including graft thrombosis, and are informed of the high risk of limb loss. (See",
"    <a class=\"local\" href=\"#H1231031621\">",
"     'Outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031542\">",
"    <span class=\"h1\">",
"     SURGICAL BYPASS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two approaches are described for open repair of popliteal artery aneurysm, a medial approach involving exclusion of the aneurysm and bypass, and a posterior approach, which involves a direct in-line repair with an interposition graft. There are no randomized data to support one approach over the other and patency rates appear equivalent. In one retrospective review of 571 patients, 87 percent were managed with a medial approach and 8 percent with a posterior approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/29\">",
"     29",
"    </a>",
"    ]. Primary vein graft patency rates were not significantly different between the medial and posterior approach (85 versus 90 percent). (See",
"    <a class=\"local\" href=\"#H604915890\">",
"     'Anatomic assessment'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H542106921\">",
"     'Open versus endovascular repair'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patency rates notwithstanding, anatomic considerations may indicate a preference for one approach over the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. When an initial surgical approach is indicated in patients with acutely thrombosed popliteal aneurysms (ie, threatened limb), or there is evidence of embolization of the tibial vessels, we suggest a medial approach which facilitates thromboembolectomy or intraoperative thrombolytic therapy. Graft patency is improved when the burden of thrombus is minimized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ]. It may be more difficult to effectively clear thrombus using a posterior approach. On the other hand, for patients with focal aneurysms confined to the popliteal fossa, we suggest a posterior approach, which minimizes the length of the graft required (see",
"    <a class=\"local\" href=\"#H1231031565\">",
"     'In-line reconstruction'",
"    </a>",
"    below). For practitioners who are not familiar with the posterior approach, the medial approach is an acceptable alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031558\">",
"    <span class=\"h2\">",
"     Aneurysm exclusion and bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the medial approach, the popliteal artery aneurysm is left in-situ and bypassed using a segment of saphenous vein (",
"    <a class=\"graphic graphic_figure graphicRef76224 \" href=\"mobipreview.htm?40/53/41815\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/33\">",
"     33",
"    </a>",
"    ]. The popliteal artery is ligated proximal and distal to the aneurysm to exclude it from the circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/34\">",
"     34",
"    </a>",
"    ]. Ligation of the popliteal artery is performed close to the aneurysm to minimize the loss of collateral vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1231031448\">",
"     'Anatomy of the popliteal fossa'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The conduit of choice for lower extremity bypass is ipsilateral great saphenous vein (reversed or nonreversed). Below-the-knee prosthetic (polytetrafluoroethylene [PTFE]) grafts have an increased risk of thrombosis and are avoided, whenever possible, for the repair of popliteal artery aneurysm. (See",
"    <a class=\"local\" href=\"#H1231031637\">",
"     'Bypass patency'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44376?source=see_link\">",
"     \"Indications for surgery in the patient with lower extremity claudication\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vein graft can be positioned adjacent the popliteal artery (ie, anatomic), or tunnelled subcutaneously along the medial aspect of the knee, depending upon the extent of the bypass, patient anatomy, and operator preference. Anatomic placement allows a straighter graft with less potential for kinking around the knee and may be more suitable for patients with muscular legs; however, the popliteal graft segment may be more difficult to appreciate on ultrasound surveillance. (See",
"    <a class=\"local\" href=\"#H1231031614\">",
"     'Graft surveillance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Extensive aneurysmal degeneration or atherosclerotic disease that affects the superficial femoral artery proximally, or popliteal artery distally (ie, at the origin of the anterior tibial artery) necessitates originating a bypass graft from the common femoral artery or extending the graft distally to one of the tibial vessels, respectively. Aggressive distal bypass to the tibial vessels may be important for optimizing outcomes. In a retrospective review of 51 popliteal aneurysm repairs (37 elective; 14 emergent), overall primary patency rates at one-year and five-years follow-up were 96 and 85 percent, and secondary patency rates were 100 and 97 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/36\">",
"     36",
"    </a>",
"    ]. In this study, the percentage of patients who had a distal infrapopliteal target for lower extremity bypass was particularly high at 57 percent. However, no significant differences in primary patency were found for popliteal versus more distal bypass targets (84 versus 87 percent at 5 years).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031565\">",
"    <span class=\"h2\">",
"     In-line reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In-line reconstruction using a posterior approach may be preferred if the aneurysm is focal and confined to the popliteal fossa (",
"    <a class=\"graphic graphic_figure graphicRef55149 \" href=\"mobipreview.htm?40/22/41317\">",
"     figure 4",
"    </a>",
"    ), especially if the aneurysm is large and compressing adjacent structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    However, this approach limits proximal vascular control, and embolectomy may be incomplete owing to an inability to direct the catheter distally into the individual tibial vessels. As such, most surgeons would not approach a thrombosed popliteal aneurysm posteriorly, particularly if outflow is compromised.",
"   </p>",
"   <p>",
"    With the posterior approach, a vein or prosthetic graft is used to reconstruct the popliteal artery. In a retrospective review of 571 patients, 45 of whom were managed with a posterior approach, vein graft and PTFE had similar one-year patency rates (85 and 81 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/29\">",
"     29",
"    </a>",
"    ]. A &lsquo;lazy&rsquo; S-shaped incision is made over the popliteal fossa to minimize problems with scar contracture. After gaining vascular control, the popliteal artery is opened and the graft sutured to normal artery proximally and distally. Upon completion of the repair, the aneurysm sac is closed over the graft, provided enough arterial wall remains (similar to other aneurysm repairs). (See",
"    <a class=\"local\" href=\"#H1231031621\">",
"     'Outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031572\">",
"    <span class=\"h2\">",
"     Surgical complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications following elective open repair of popliteal aneurysms are uncommon. The most common postoperative problems involve the surgical wound, occurring in about 5 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/8\">",
"     8",
"    </a>",
"    ]. Both local and systemic complications are greater in patients undergoing open repair of popliteal aneurysms for acute ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/8,22\">",
"     8,22",
"    </a>",
"    ]. Early graft failure is uncommon.",
"   </p>",
"   <p>",
"    Graft patency rates depend upon the clinical situation leading to popliteal aneurysm repair, the status of the tibial outflow, and the type of conduit used. (See",
"    <a class=\"local\" href=\"#H1231031621\">",
"     'Outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Complications that are unique to lower extremity bypass for popliteal artery aneurysm include late expansion of the residual aneurysm sac, aneurysm extension, and vein graft aneurysms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Late expansion of aneurysm sac &ndash; In spite of popliteal artery exclusion (ligation proximal and distal to the aneurysm at the time of popliteal artery bypass), aneurysm sac expansion occurs in up to 30 percent of patients due to persistent backflow from one or more of the geniculate vessels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/34,39-44\">",
"       34,39-44",
"      </a>",
"      ]. This complication usually occurs later in the postoperative course. In one retrospective review, perfusion of the aneurysm sac was identified at a median of six years after primary repair (range 1 to 20 years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/45\">",
"       45",
"      </a>",
"      ]. Rupture of the residual popliteal aneurysm has been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/26\">",
"       26",
"      </a>",
"      ]. If the residual sac continues to expand or the patient becomes symptomatic, the vessel(s) providing flow into the excluded aneurysm need(s) to be identified and ligated. This is usually accomplished using a posterior approach. The aneurysm sac is identified and opened, and the branches are ligated from within the sac.",
"      <br/>",
"      <br/>",
"      Because of the nature of the open posterior approach, in-line reconstruction is associated with a much lower risk of postoperative sac expansion compared with the medial approach. In one retrospective review of 571 patients, the risk of expansion following posterior repair was 8 percent compared with 33 percent for the medial approach [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Aneurysm",
"      <span class=\"nowrap\">",
"       extension/vein",
"      </span>",
"      graft aneurysm &ndash; Aneurysmal degeneration of the arterial wall may continue following aneurysm repair. Further aneurysmal expansion of the proximal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      distal popliteal artery has the same risks for thrombosis or embolization as the original aneurysm. Lifelong follow-up is important to identify and treat the ongoing disease process [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/46-48\">",
"       46-48",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1231031614\">",
"       'Graft surveillance'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Vein graft aneurysm &ndash; Vein bypass grafts used in patients treated for aneurysmal disease may be more prone to aneurysmal degeneration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/47,49\">",
"       47,49",
"      </a>",
"      ]. Vein graft aneurysms are more common after the repair of popliteal artery aneurysm compared with vein bypass grafting for atherosclerotic occlusive disease. In one study of 138 patients, 4 percent of patients with popliteal artery aneurysms managed with vein bypass grafts developed a vein graft aneurysm. (See",
"      <a class=\"local\" href=\"#H1231031614\">",
"       'Graft surveillance'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031579\">",
"    <span class=\"h1\">",
"     ENDOVASCULAR ANEURYSM REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal popliteal aneurysms that do not extend into the distal popliteal artery are the most suitable for endovascular repair. More aggressive uses of endovascular stent-grafts include multiple stents for the repair of more extensive aneurysms that involve the superficial femoral artery, and stenting of ruptured popliteal artery aneurysm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early stents-grafts for the repair of popliteal artery aneurysm were homemade and fashioned from balloon-expandable stents attached to a 6 mm polytetrafluoroethylene graft (PTFE), and on occasion, this type of graft may still be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Commercially available stent-grafts are composed of a self-expanding metal (eg, nitinol) framework covered with fabric. There are no randomized trials to guide specific device selection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1300235131\">",
"    <span class=\"h2\">",
"     Stent-graft placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stent-grafts are placed percutaneously in an interventional suite or an appropriately equipped operating room, or if the need dictates, via a common femoral artery cut-down in the operating room. Fluoroscopy is used to guide stent-graft positioning.",
"   </p>",
"   <p>",
"    Common femoral artery access can be obtained on the same side of the aneurysm (antegrade puncture), threading the guidewires and catheters down the leg to the aneurysm, or contralateral to the aneurysm (retrograde puncture), threading the guidewire and catheters up and over the aortic bifurcation and down to the aneurysm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once femoral access is achieved, an arteriogram is performed to evaluate the vasculature proximal and distal to the aneurysm. Patients who have evidence of prior embolization may benefit from thrombolytic therapy. Inadequate restoration of flow in continuity with the popliteal artery precludes placement of a stent-graft. These patients will require bypass to one of the tibial vessels. (See",
"    <a class=\"local\" href=\"#H1231031542\">",
"     'Surgical bypass'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A soft guidewire is advanced through the popliteal aneurysm into one of the tibial vessels. The initial wire is replaced with a catheter through which a stiffer wire is placed. An adequate diameter and longer sheath is placed to protect the stent-graft as it is passed to the aneurysm site. The device is advanced over the stiff wire and additional imaging performed to ensure accurate placement of the device. The stent-graft should overlap the proximal and distal normal artery by at least 1 cm (",
"    <a class=\"graphic graphic_figure graphicRef68952 \" href=\"mobipreview.htm?31/40/32384\">",
"     figure 5",
"    </a>",
"    ). Care is taken to avoid points of vessel flexion to avoid kinking the stent which can potentially lead to stent-graft thrombosis. Some studies have shown that the primary site of arterial flexion occurs at the superior margin of the patella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/53\">",
"     53",
"    </a>",
"    ]. When multiple stents are needed, stent overlap in this region needs to be long enough to ensure that kinking does not occur and that components do not separate. (See",
"    <a class=\"local\" href=\"#H601500443\">",
"     'Suitability for endovascular repair'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Once the proper position is confirmed, the graft is deployed from its sheath and an appropriately sized balloon is inflated within the proximal and distal graft to ensure an adequate seal. Repeat arteriography is performed to confirm graft position and absence of any endoleaks. Due to the size of the graft delivery sheath, a percutaneous closure device is often used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031593\">",
"    <span class=\"h2\">",
"     Stent-graft complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of popliteal artery stent-grafting are similar to those of any peripheral artery stent. These include bleeding, hematoma, pseudoaneurysm, stent-graft kinking, migration or fracture, or stent thrombosis (early or late). Endoleak is a complication that is unique to endograft repair of arterial aneurysm.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stent-graft thrombosis &ndash; In the early experience of popliteal aneurysm stent-grafting, immediate postintervention failures due to thrombosis were common. The administration of periprocedural antiplatelet agents has decreased the incidence of early thrombosis (see",
"      <a class=\"local\" href=\"#H1231031607\">",
"       'Antiplatelet therapy'",
"      </a>",
"      below). Aggressive graft over-sizing can also cause thrombosis due to incomplete graft unfolding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/47\">",
"       47",
"      </a>",
"      ]. Other factors that increase the risk for thrombosis include stent kinking, stent fracture, the use of multiple stents, and poor outflow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/5,6,54\">",
"       5,6,54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endoleak &ndash; Endoleaks are classified in a similar manner to those complicating the endovascular repair of abdominal aortic aneurysm (",
"      <a class=\"graphic graphic_figure graphicRef64707 \" href=\"mobipreview.htm?36/13/37074\">",
"       figure 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=see_link&amp;anchor=H1191826906#H1191826906\">",
"       \"Complications of endovascular abdominal aortic repair\", section on 'Endoleak'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Endoleak occurs in 10 to 20 percent of patients following popliteal artery aneurysm repair [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/3,10,16,18\">",
"       3,10,16,18",
"      </a>",
"      ]. Endoleak most commonly develops at the stent-graft fixation points (type I). If a type I endoleak is identified at the time of completion arteriography, additional balloon angioplasty or stent-graft placement is performed to remedy the leak. With time, arterial wall aneurysmal degeneration may change the configuration of the popliteal aneurysm, potentially leading to stent-graft migration and a delayed type I leak [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/23\">",
"       23",
"      </a>",
"      ]. Ongoing surveillance is necessary to detect these leaks. Additional stenting or conversion to an open surgical bypass may be required. (See",
"      <a class=\"local\" href=\"#H1231031614\">",
"       'Graft surveillance'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Type II endoleaks are due to retrograde flow from branch vessels off the aneurysm sac. Type II endoleak can be managed with ultrasound-guided thrombin injection into the aneurysm sac. Ongoing type II leak that does not resolve with thrombin injection can be approached using percutaneous coil embolization (similar with endoleak associated with endovascular abdominal aortic aneurysm repair) or a surgical approach that involves opening of the sac and oversewing the leaking branches, as described above for expanding sacs following open bypass and exclusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=see_link&amp;anchor=H1191826906#H1191826906\">",
"       \"Complications of endovascular abdominal aortic repair\", section on 'Endoleak'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H1231031572\">",
"       'Surgical complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stent fracture &ndash; Stent fractures can occur at points of severe flexion and may also be seen in overlapping stents. One study found stent fracture incidences in 16 percent of the patients studied [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/54\">",
"       54",
"      </a>",
"      ]. However, overall stent-graft patency in those with stent fracture was not significantly different compared with those without stent graft fracture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031600\">",
"    <span class=\"h1\">",
"     PERIOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postprocedural course depends upon the initial clinical presentation and type of repair.",
"   </p>",
"   <p>",
"    Following elective endovascular repair, the patient is admitted for observation and maintained at bedrest for a minimum of six hours following the procedure to ensure adequate closure of the groin puncture site. The patient is allowed to ambulate thereafter. Although there are no studies directly evaluating the optimal period of bedrest following endovascular popliteal aneurysm repair, randomized trials following percutaneous intervention (mostly cardiac) have used protocols that immobilize the patient for three to eight hours following removal of the groin sheath [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/55-64\">",
"     55-64",
"    </a>",
"    ]. One randomized trial found no difference in access site complications for three hours compared with longer periods of immobilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/57\">",
"     57",
"    </a>",
"    ]. However, we prefer to immobilize the patient for at least six hours because the size of the sheath required for endovascular repair of popliteal artery aneurysm is larger (7 or 8F) compared with that needed for percutaneous coronary intervention, and groin complications such as groin hematoma or access vessel thrombosis risk compromising the popliteal revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/65\">",
"     65",
"    </a>",
"    ]. A shorter period of immobilization may be allowed if a vascular closure device is used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=see_link&amp;anchor=H678090984#H678090984\">",
"     \"Complications of diagnostic cardiac catheterization\", section on 'Closure devices'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following open surgical or endovascular repair for critical ischemia, the patient is transferred to a monitored care setting (intensive care unit, step down), the intensity of which depends upon the patient's comorbidities. The integrity of the repair is monitored with frequent (every six hours) pulse checks. The patient is placed at bedrest overnight and is generally allowed to ambulate the next day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107105279\">",
"    <span class=\"h2\">",
"     Extremity compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute limb-threatening ischemia who have not already undergone fasciotomy are monitored for compartment syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Those who have fasciotomy wounds are managed accordingly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3400?source=see_link\">",
"     \"Patient management following extremity fasciotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031607\">",
"    <span class=\"h2\">",
"     Antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients in whom popliteal artery aneurysm stenting is scheduled or anticipated, we recommend periprocedural antiplatelet therapy. In retrospective reviews, antiplatelet therapy is associated with a lower incidence of early stent-graft thrombosis following endovascular repair of popliteal artery aneurysm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/50,68-70\">",
"     50,68-70",
"    </a>",
"    ]. Patients with lower extremity bypass may also benefit from antithrombotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19370?source=see_link&amp;anchor=H519589654#H519589654\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\", section on 'Antithrombotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) is recommended for all patients with peripheral artery disease, including those with large artery aneurysms, and should be initiated for those not already on chronic therapy, and continued indefinitely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/2,14,71\">",
"     2,14,71",
"    </a>",
"    ]. We give aspirin 325 to 650 mg daily starting at least 48 hours before the procedure or, if within 48 hours of the procedure, a loading dose of aspirin 650 mg given at least four hours before the procedure.",
"   </p>",
"   <p>",
"    Following the procedure, we suggest dual antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) for at least four weeks if the risk for bleeding is low. Clopidogrel is commonly used following endovascular stenting at other sites and has been adopted by some following endovascular repair of popliteal artery aneurysm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/50,68-70\">",
"     50,68-70",
"    </a>",
"    ]. Postoperative clopidogrel may improve outcomes of popliteal aneurysm stent-graft repair, but randomized trials are needed to verify these observational data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1231031699\">",
"     'Stent-graft patency'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38921?source=see_link&amp;anchor=H909615712#H909615712\">",
"     \"Percutaneous interventional procedures in the patient with lower extremity claudication\", section on 'Antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031614\">",
"    <span class=\"h2\">",
"     Graft surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following popliteal aneurysm repair, patients are followed with physical examination and noninvasive vascular lab studies. A duplex scan of the bypass graft or stent-graft (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73753 \" href=\"mobipreview.htm?29/51/30513\">",
"     image 1",
"    </a>",
"    ) is performed initially postoperatively to establish a baseline, and then at six months to identify areas of vein graft or stent-graft stenosis, aneurysm sac enlargement, or endoleak. Thereafter, the study is obtained annually, provided the patient does not become symptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/21,72\">",
"     21,72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19370?source=see_link&amp;anchor=H519589146#H519589146\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\", section on 'Postoperative follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031621\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major endpoints of popliteal aneurysm repair (eg, patency, limb salvage, mortality) are affected by the nature of the presenting symptoms and signs, type of repair, quality of distal runoff, and risk factors for disease progression (eg, smoking) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/1,5,8,9\">",
"     1,5,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H779515438\">",
"    <span class=\"h2\">",
"     Definition of terms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In discussing outcomes of open and endovascular popliteal aneurysm repair, several terms need to be understood. These include primary patency, assisted-primary patency, and secondary patency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/73\">",
"     73",
"    </a>",
"    ], each of which is defined for a specified period of follow-up (eg, three-year primary patency).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary patency means that the revascularized region (bypass or stent) is open and has not required any form of reintervention.",
"     </li>",
"     <li>",
"      Assisted-primary patency means that the revascularized region (bypass or stent) is open but has required reintervention (surgery or stent) to prevent impending occlusion or progression of stenosis.",
"     </li>",
"     <li>",
"      Secondary patency means that the revascularized region (bypass or stent) has occluded at some point in the past but patency of the revascularized region was restored with some form of intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031628\">",
"    <span class=\"h2\">",
"     Surgical repair",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031637\">",
"    <span class=\"h3\">",
"     Bypass patency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective reviews of popliteal aneurysm bypass report overall five-year primary patency rates between 76 and 95 percent and secondary patency rates between 78 and 87 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/5,8,45,74-77\">",
"     5,8,45,74-77",
"    </a>",
"    ]. Cumulative primary and secondary patency rates at 10 years are 59 and 66 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H779515438\">",
"     'Definition of terms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patency rates are higher with great saphenous vein grafts compared with polytetrafluoroethylene (PTFE) grafts. In one large retrospective review, primary and secondary patency rates for vein grafts were significantly better compared with PTFE grafts (85 and 94 percent versus 50 and 63 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In other reviews, the presence of adequate runoff (three vessels patent to the ankle) and a more proximal site of the distal anastomosis",
"    <strong>",
"    </strong>",
"    correlate with better long-term patency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/5,78,79\">",
"     5,78,79",
"    </a>",
"    ]. One retrospective review found that primary bypass failure was associated with smoking and poor distal runoff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/5\">",
"     5",
"    </a>",
"    ]. However, another study found no significant correlation with runoff status and primary graft patency at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/6\">",
"     6",
"    </a>",
"    ]. In this study, cumulative five-year patency was 95 percent; none of the patients were treated with prosthetic grafts. Ten patients with single vessel runoff did not experience graft-related problems.",
"   </p>",
"   <p>",
"    The greatest influence on outcome and patency following open bypass for popliteal aneurysm repair appears to be the clinical circumstance under which the repair is performed. Elective popliteal artery bypass is associated with significantly improved outcomes (ie, graft patency, limb salvage) compared with bypass performed for acute ischemic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/1,77,78\">",
"     1,77,78",
"    </a>",
"    ]. In a retrospective review of 289 patients followed over a mean of four years, perioperative (30-day) graft thrombosis rates were 1, 4, and 9 percent for asymptomatic patients, patients with chronic symptoms, and those with acute ischemia, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of 32 observational studies of acutely thrombosed popliteal aneurysms identified a significant difference in one-year primary graft patency rates in patients who had some form of thrombolysis (preoperative or intraoperative) compared with those who did not (79 versus 71 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/24\">",
"     24",
"    </a>",
"    ]. However, a significant difference in limb salvage rates was not seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031678\">",
"    <span class=\"h3\">",
"     Limb loss following surgical bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limb loss following elective popliteal artery bypass grafting is rare (&lt;1 percent). Overall long-term limb salvage rates (elective and emergent) are between 96 and 98 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/5,36\">",
"     5,36",
"    </a>",
"    ]. One-year and three-year amputation rates range from 0 to 11 percent and 0 to 22 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large retrospective review, a Cox regression model determined that advancing age, emergency procedure, and prosthetic graft were independently associated with an increased incidence of amputation in the long-term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/29\">",
"     29",
"    </a>",
"    ]. When the indication for repair is acute aneurysm thrombosis, amputation rates range from 5 to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/5,8,24,78\">",
"     5,8,24,78",
"    </a>",
"    ]. Limb loss is most likely to occur within the first month following bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/78\">",
"     78",
"    </a>",
"    ]. In a retrospective review of 289 patients followed over a mean of 4.3 years, outcomes for differing clinical presentations were evaluated. These included patients with no symptoms (40 percent), chronic symptoms (39 percent), or acute ischemia (21 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/8\">",
"     8",
"    </a>",
"    ]. All early amputations occurred in patients with acute ischemia and there was no limb loss in patients with chronic symptoms when great saphenous vein was used as a conduit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/8\">",
"     8",
"    </a>",
"    ]. The overall five-year limb salvage rate was 85 percent in patients with acute ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031685\">",
"    <span class=\"h3\">",
"     Mortality following bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elective popliteal aneurysm repair is associated with low (&lt;1 percent) mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/8,45\">",
"     8,45",
"    </a>",
"    ]. Mortality rates for patients undergoing emergent repair range from 3 to 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/5,24\">",
"     5,24",
"    </a>",
"    ]. Late survival is similar to that of patients with atherosclerotic peripheral artery disease with studies finding 5-year and 10-year survival rates of 70 to 85 percent and 44 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/5,36,45\">",
"     5,36,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031692\">",
"    <span class=\"h2\">",
"     Endovascular repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary factors affecting the outcome of stent-graft repair of popliteal artery aneurysms are suitable aneurysm anatomy and postoperative antiplatelet therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031699\">",
"    <span class=\"h3\">",
"     Stent-graft patency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate technical success is achieved in 96 to 100 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/18,50,69,80-83\">",
"     18,50,69,80-83",
"    </a>",
"    ]. Following endovascular repair of popliteal artery aneurysm, small series show primary patency rates ranging between 80 to 94 percent at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/16,19,50,68,84-87\">",
"     16,19,50,68,84-87",
"    </a>",
"    ]. Secondary patency ranges from 75 and 100 percent at one year and 82 to 88 percent at three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/10,16,19,50,68,81,84-87\">",
"     10,16,19,50,68,81,84-87",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H779515438\">",
"     'Definition of terms'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542127374\">",
"    <span class=\"h3\">",
"     Limb loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of limb loss following elective popliteal artery endovascular aneurysm repair is low (&lt;1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/10,87\">",
"     10,87",
"    </a>",
"    ]. Overall amputation rates are 0 to 3 percent at one-year follow-up and 3 to 4 percent at three-year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/45/31450/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1231031721\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Popliteal artery aneurysm presents in a variety of ways. Many patients are asymptomatic, while others have symptoms referable to the aneurysm, such as pain with ambulation (claudication) or acute limb ischemia due to aneurysm thrombosis or distal embolization. (See",
"      <a class=\"local\" href=\"#H1231031427\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link\">",
"       \"Popliteal artery aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Repair of popliteal artery aneurysm is indicated for patients with symptomatic popliteal artery aneurysms (eg, acute limb ischemia, disabling claudication), and in selected asymptomatic patients depending upon the size of the aneurysm and presence of thrombus. (See",
"      <a class=\"local\" href=\"#H1231031434\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=see_link&amp;anchor=H20038379#H20038379\">",
"       \"Popliteal artery aneurysm\", section on 'Indications for repair'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The goal of popliteal artery aneurysm repair is to eliminate the aneurysm from the circulation and maintain perfusion to the extremity. Open surgical bypass and endovascular stent-grafting each accomplish these goals with differing advantages, disadvantages, and types of complications. (See",
"      <a class=\"local\" href=\"#H1231031542\">",
"       'Surgical bypass'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1231031579\">",
"       'Endovascular aneurysm repair'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to repair of popliteal artery aneurysms, the patient's clinical condition, vascular anatomy (including the presence of other aneurysms), and medical comorbidities are evaluated to define the patient&rsquo;s risk for repair and to aid in choosing the approach to repair. (See",
"      <a class=\"local\" href=\"#H1231031455\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We advocate an individualized approach to popliteal aneurysm repair taking into account the degree of any acute limb ischemia, the patient&rsquo;s medical comorbidities, and their vascular anatomy (suitability for endograft, status of the",
"      <span class=\"nowrap\">",
"       proximal/distal",
"      </span>",
"      circulation, coexistent aneurysm, availability of vein conduit). (See",
"      <a class=\"local\" href=\"#H542106921\">",
"       'Open versus endovascular repair'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1231031621\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Under elective circumstances:",
"      <br/>",
"      <br/>",
"      For patients with a high perioperative surgical risk and suitable anatomy for endografting, we suggest endovascular repair rather than open repair (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H601500443\">",
"       'Suitability for endovascular repair'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients with low perioperative surgical risk and who have adequate vein conduit, we suggest open surgical repair rather than endovascular repair (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Endovascular repair is associated with an increased risk of early (30-day) reintervention and early (30-day) graft thrombosis, but longer-term secondary patency rates appear to be similar to open repair. In those without adequate vein conduit, endografting is an acceptable alternative provided the patient&rsquo;s vascular anatomy is suitable for endograft placement.",
"      <br/>",
"      <br/>",
"      For patients in whom an open surgical approach is chosen and the popliteal artery aneurysm is focal and confined to the popliteal fossa, we suggest a posterior approach rather than a medial approach (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For practitioners who are not familiar with the technique, a medial approach is an acceptable alternative. More extensive aneurysms that involve the superficial femoral artery or distal popliteal artery necessitate a medial approach.",
"     </li>",
"     <li>",
"      Under emergent circumstances (ie, acute thrombosis, rupture):",
"      <br/>",
"      <br/>",
"      Thrombolytic therapy is appropriate for most patients with acute limb ischemia of less than 14 days duration who have a low risk for developing myonecrosis and ischemic nerve damage during the period required to achieve revascularization. This issue is discussed in more detail elsewhere. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13368?source=see_link&amp;anchor=H506059593#H506059593\">",
"       \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If distal runoff (two or three vessel runoff) is adequate following thrombolytic therapy, the decision for open repair versus endovascular repair is based upon the level of perioperative surgical risk and anatomic suitability, as with elective repair.",
"      <br/>",
"      <br/>",
"      If distal runoff is not adequate to support endovascular repair following thrombolysis but a target distal to the popliteal artery is identified, we suggest revascularization to that target (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Furthermore, we suggest using a medial approach which facilitates thromboembolectomy or intraoperative thrombolytic therapy rather than a posterior approach (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients in whom popliteal artery aneurysm stenting is scheduled or anticipated, we recommend periprocedural antiplatelet therapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For those patients not on chronic aspirin therapy, we give aspirin 325 to 650 mg daily starting at least 48 hours before the procedure or, if within 48 hours of the procedure, a loading dose of aspirin 650 mg given at least four hours before the procedure. Following popliteal artery aneurysm stenting for patients in whom the risk of bleeding is low, we suggest dual antiplatelet therapy (aspirin plus clopidogrel) for at least four weeks (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1231031607\">",
"       'Antiplatelet therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following open or endovascular repair of popliteal artery aneurysm, duplex ultrasound surveillance should be performed postoperatively to establish a baseline, and then at six months postoperatively to identify areas of stenosis in the graft or stent-graft, aneurysm sac enlargement, and for endovascular repair, endoleak, or stent-graft fracture. Thereafter, duplex surveillance is obtained annually unless symptoms develop. (See",
"      <a class=\"local\" href=\"#H1231031614\">",
"       'Graft surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The outcomes of popliteal artery aneurysm repair (eg, graft patency, limb salvage, mortality) are affected by the nature of the presenting symptoms and signs, type of repair, quality of distal runoff, and risk factors for aneurysmal disease progression (eg, smoking) and type of repair. (See",
"      <a class=\"local\" href=\"#H1231031621\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/1\">",
"      Pulli R, Dorigo W, Troisi N, et al. Surgical management of popliteal artery aneurysms: which factors affect outcomes? J Vasc Surg 2006; 43:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/2\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/3\">",
"      Tsilimparis N, Dayama A, Ricotta JJ 2nd. Open and endovascular repair of popliteal artery aneurysms: tabular review of the literature. Ann Vasc Surg 2013; 27:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/4\">",
"      Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/5\">",
"      Martelli E, Ippoliti A, Ventoruzzo G, et al. Popliteal artery aneurysms. Factors associated with thromboembolism and graft failure. Int Angiol 2004; 23:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/6\">",
"      Hagino RT, Fujitani RM, Dawson DL, et al. Does infrapopliteal arterial runoff predict success for popliteal artery aneurysmorrhaphy? Am J Surg 1994; 168:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/7\">",
"      Kropman RH, Kiela G, Moll FL, de Vries JP. Variations in anatomy of the popliteal artery and its side branches. Vasc Endovascular Surg 2011; 45:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/8\">",
"      Huang Y, Gloviczki P, Noel AA, et al. Early complications and long-term outcome after open surgical treatment of popliteal artery aneurysms: is exclusion with saphenous vein bypass still the gold standard? J Vasc Surg 2007; 45:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/9\">",
"      Ravn H, Bj&ouml;rck M. Popliteal artery aneurysm with acute ischemia in 229 patients. Outcome after thrombolytic and surgical therapy. Eur J Vasc Endovasc Surg 2007; 33:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/10\">",
"      Midy D, Berard X, Ferdani M, et al. A retrospective multicenter study of endovascular treatment of popliteal artery aneurysm. J Vasc Surg 2010; 51:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/11\">",
"      Debing E, Van den Brande P, van Tussenbroek F, et al. Intra-arterial thrombolysis followed by elective surgery for thrombo-embolic popliteal aneurysms. Acta Chir Belg 1997; 97:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/12\">",
"      Marty B, Wicky S, Ris HB, et al. Success of thrombolysis as a predictor of outcome in acute thrombosis of popliteal aneurysms. J Vasc Surg 2002; 35:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/13\">",
"      Greenberg R, Wellander E, Nyman U, et al. Aggressive treatment of acute limb ischemia due to thrombosed popliteal aneurysms. Eur J Radiol 1998; 28:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/14\">",
"      2011 WRITING GROUP MEMBERS, 2005 WRITING COMMITTEE MEMBERS, ACCF/AHA TASK FORCE MEMBERS. 2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 124:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/15\">",
"      Zimmermann A, Schoenberger T, Saeckl J, et al. Eligibility for endovascular technique and results of the surgical approach to popliteal artery aneurysms at a single center. Ann Vasc Surg 2010; 24:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/16\">",
"      Moore RD, Hill AB. Open versus endovascular repair of popliteal artery aneurysms. J Vasc Surg 2010; 51:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/17\">",
"      Veith FJ, Abbott WM, Yao JS, et al. Guidelines for development and use of transluminally placed endovascular prosthetic grafts in the arterial system. Endovascular Graft Committee. J Vasc Surg 1995; 21:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/18\">",
"      Antonello M, Frigatti P, Battocchio P, et al. Open repair versus endovascular treatment for asymptomatic popliteal artery aneurysm: results of a prospective randomized study. J Vasc Surg 2005; 42:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/19\">",
"      Lovegrove RE, Javid M, Magee TR, Galland RB. Endovascular and open approaches to non-thrombosed popliteal aneurysm repair: a meta-analysis. Eur J Vasc Endovasc Surg 2008; 36:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/20\">",
"      Curi MA, Geraghty PJ, Merino OA, et al. Mid-term outcomes of endovascular popliteal artery aneurysm repair. J Vasc Surg 2007; 45:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/21\">",
"      Stone PA, Armstrong PA, Bandyk DF, et al. The value of duplex surveillance after open and endovascular popliteal aneurysm repair. J Vasc Surg 2005; 41:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/22\">",
"      Michaels JA, Galland RB. Management of asymptomatic popliteal aneurysms: the use of a Markov decision tree to determine the criteria for a conservative approach. Eur J Vasc Surg 1993; 7:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/23\">",
"      Antonello M, Frigatti P, Battocchio P, et al. Endovascular treatment of asymptomatic popliteal aneurysms: 8-year concurrent comparison with open repair. J Cardiovasc Surg (Torino) 2007; 48:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/24\">",
"      Kropman RH, Schrijver AM, Kelder JC, et al. Clinical outcome of acute leg ischaemia due to thrombosed popliteal artery aneurysm: systematic review of 895 cases. Eur J Vasc Endovasc Surg 2010; 39:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/25\">",
"      Gibbons CP. Thrombolysis or immediate surgery for thrombosed popliteal aneurysms? Eur J Vasc Endovasc Surg 2010; 39:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/26\">",
"      Illig KA, Eagleton MJ, Shortell CK, et al. Ruptured popliteal artery aneurysm. J Vasc Surg 1998; 27:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/27\">",
"      Ihlberg LH, Roth WD, Alb&auml;ck NA, et al. Successful percutaneous endovascular treatment of a ruptured popliteal artery aneurysm. J Vasc Surg 2000; 31:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/28\">",
"      Bani-Hani MG, Elnahas L, Plant GR, et al. Endovascular management of ruptured infected popliteal artery aneurysm. J Vasc Surg 2012; 55:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/29\">",
"      Ravn H, Wanhainen A, Bj&ouml;rck M, Swedish Vascular Registry (Swedvasc). Surgical technique and long-term results after popliteal artery aneurysm repair: results from 717 legs. J Vasc Surg 2007; 46:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/30\">",
"      Kropman RH, van Santvoort HC, Teijink J, et al. The medial versus the posterior approach in the repair of popliteal artery aneurysms: a multicenter case-matched study. J Vasc Surg 2007; 46:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/31\">",
"      Mahmood A, Salaman R, Sintler M, et al. Surgery of popliteal artery aneurysms: a 12-year experience. J Vasc Surg 2003; 37:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/32\">",
"      Bisdas T, Paraskevas KI, Pichlmaier M, et al. Dorsal (posterior) versus medial approach for the surgical repair of popliteal artery aneurysms. Angiology 2010; 61:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/33\">",
"      Edwards WS. Exslusion and saphenous vein bypass of popliteal aneurysms. Surg Gynecol Obstet 1969; 128:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/34\">",
"      Ebaugh JL, Morasch MD, Matsumura JS, et al. Fate of excluded popliteal artery aneurysms. J Vasc Surg 2003; 37:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/35\">",
"      Ascher E, Markevich N, Schutzer RW, et al. Small popliteal artery aneurysms: are they clinically significant? J Vasc Surg 2003; 37:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/36\">",
"      Aulivola B, Hamdan AD, Hile CN, et al. Popliteal artery aneurysms: a comparison of outcomes in elective versus emergent repair. J Vasc Surg 2004; 39:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/37\">",
"      Beseth BD, Moore WS. The posterior approach for repair of popliteal artery aneurysms. J Vasc Surg 2006; 43:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/38\">",
"      Zaraca F, Ponzoni A, Stringari C, et al. The posterior approach in the treatment of popliteal artery aneurysm: feasibility and analysis of outcome. Ann Vasc Surg 2010; 24:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/39\">",
"      Mehta M, Champagne B, Darling RC 3rd, et al. Outcome of popliteal artery aneurysms after exclusion and bypass: significance of residual patent branches mimicking type II endoleaks. J Vasc Surg 2004; 40:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/40\">",
"      Battey PM, Skardasis GM, McKinnon WM. Rupture of a previously bypassed popliteal aneurysm: a case report. J Vasc Surg 1987; 5:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/41\">",
"      Deglise S, Qanadli SD, Rizzo E, et al. Long-term follow-up of surgically excluded popliteal artery aneurysms with multi-slice CT angiography and Doppler ultrasound. Eur Radiol 2006; 16:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/42\">",
"      Vrijenhoek JE, Mackaay AJ, Cornelissen SA, Moll FL. Long-term outcome of popliteal artery aneurysms after ligation and bypass. Vasc Endovascular Surg 2011; 45:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/43\">",
"      Bellosta R, Sarcina A, Luzzani L, et al. Fate of popliteal artery aneurysms after exclusion and bypass. Ann Vasc Surg 2010; 24:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/44\">",
"      Kirkpatrick UJ, McWilliams RG, Martin J, et al. Late complications after ligation and bypass for popliteal aneurysm. Br J Surg 2004; 91:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/45\">",
"      Davies RS, Wall M, Rai S, et al. Long-term results of surgical repair of popliteal artery aneurysm. Eur J Vasc Endovasc Surg 2007; 34:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/46\">",
"      Dawson I, van Bockel JH, Brand R, Terpstra JL. Popliteal artery aneurysms. Long-term follow-up of aneurysmal disease and results of surgical treatment. J Vasc Surg 1991; 13:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/47\">",
"      Loftus IM, McCarthy MJ, Lloyd A, et al. Prevalence of true vein graft aneurysms: implications for aneurysm pathogenesis. J Vasc Surg 1999; 29:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/48\">",
"      Jones WT 3rd, Hagino RT, Chiou AC, et al. Graft patency is not the only clinical predictor of success after exclusion and bypass of popliteal artery aneurysms. J Vasc Surg 2003; 37:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/49\">",
"      Ravn H, Wanhainen A, Bj&ouml;rck M. Risk of new aneurysms after surgery for popliteal artery aneurysm. Br J Surg 2008; 95:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/50\">",
"      Rajasinghe HA, Tzilinis A, Keller T, et al. Endovascular exclusion of popliteal artery aneurysms with expanded polytetrafluoroethylene stent-grafts: early results. Vasc Endovascular Surg 2006; 40:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/51\">",
"      Marin ML, Veith FJ, Panetta TF, et al. Transfemoral endoluminal stented graft repair of a popliteal artery aneurysm. J Vasc Surg 1994; 19:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/52\">",
"      Yilmaz S, Sindel T, L&uuml;leci E. Ultrasound-guided retrograde popliteal artery catheterization: experience in 174 consecutive patients. J Endovasc Ther 2005; 12:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/53\">",
"      Kr&ouml;ger K, Santosa F, Goyen M. Biomechanical incompatibility of popliteal stent placement. J Endovasc Ther 2004; 11:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/54\">",
"      Tielliu IF, Zeebregts CJ, Vourliotakis G, et al. Stent fractures in the Hemobahn/Viabahn stent graft after endovascular popliteal aneurysm repair. J Vasc Surg 2010; 51:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/55\">",
"      Lehmann KG, Ferris ST, Heath-Lange SJ. Maintenance of hemostasis after invasive cardiac procedures: implications for outpatient catheterization. J Am Coll Cardiol 1997; 30:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/56\">",
"      Walker SB, Cleary S, Higgins M. Comparison of the FemoStop device and manual pressure in reducing groin puncture site complications following coronary angioplasty and coronary stent placement. Int J Nurs Pract 2001; 7:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/57\">",
"      Walker S, Jen C, McCosker F, Cleary S. Comparison of complications in percutaneous coronary intervention patients mobilized at 3, 4, and 6 hours after femoral arterial sheath removal. J Cardiovasc Nurs 2008; 23:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/58\">",
"      Fowlow B, Price P, Fung T. Ambulation after sheath removal: a comparison of 6 and 8 hours of bedrest after sheath removal in patients following a PTCA procedure. Heart Lung 1995; 24:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/59\">",
"      Koch KT, Piek JJ, de Winter RJ, et al. Early ambulation after coronary angioplasty and stenting with six French guiding catheters and low-dose heparin. Am J Cardiol 1997; 80:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/60\">",
"      Koch KT, Piek JJ, de Winter RJ, et al. Two hour ambulation after coronary angioplasty and stenting with 6 F guiding catheters and low dose heparin. Heart 1999; 81:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/61\">",
"      Vlasic W, Almond D, Massel D. Reducing bedrest following arterial puncture for coronary interventional procedures--impact on vascular complications: the BAC Trial. J Invasive Cardiol 2001; 13:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/62\">",
"      Tagney J, Lackie D. Bed-rest post-femoral arterial sheath removal--what is safe practice? A clinical audit. Nurs Crit Care 2005; 10:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/63\">",
"      Benson LM, Wunderly D, Perry B, et al. Determining best practice: comparison of three methods of femoral sheath removal after cardiac interventional procedures. Heart Lung 2005; 34:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/64\">",
"      Schwarz T, Rastan A, Pochert V, et al. Mechanical compression versus haemostatic wound dressing after femoral artery sheath removal: a prospective, randomized study. Vasa 2009; 38:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/65\">",
"      Islam MA, George AK, Norris M. Popliteal artery embolization with the Mynx closure device. Catheter Cardiovasc Interv 2010; 75:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/66\">",
"      Katz SG, Abando A. The use of closure devices. Surg Clin North Am 2004; 84:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/67\">",
"      Kalapatapu VR, Ali AT, Masroor F, et al. Techniques for managing complications of arterial closure devices. Vasc Endovascular Surg 2006; 40:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/68\">",
"      Tielliu IF, Verhoeven EL, Zeebregts CJ, et al. Endovascular treatment of popliteal artery aneurysms: results of a prospective cohort study. J Vasc Surg 2005; 41:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/69\">",
"      Tielliu IF, Verhoeven EL, Zeebregts CJ, et al. Endovascular treatment of popliteal artery aneurysms: is the technique a valid alternative to open surgery? J Cardiovasc Surg (Torino) 2007; 48:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/70\">",
"      Garg K, Rockman CB, Kim BJ, et al. Outcome of endovascular repair of popliteal artery aneurysm using the Viabahn endoprosthesis. J Vasc Surg 2012; 55:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/71\">",
"      Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e669S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/72\">",
"      American College of Cardiology Foundation(ACCF), American College of Radiology(ACR), American Institute of Ultrasound in Medicine(AIUM), et al. ACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS 2012 appropriate use criteria for peripheral vascular ultrasound and physiological testing part I: arterial ultrasound and physiological testing: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American College of Radiology, American Institute of Ultrasound in Medicine, American Society of Echocardiography, American Society of Nephrology, Intersocietal Commission for the Accreditation of Vascular Laboratories, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. J Vasc Surg 2012; 56:e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/73\">",
"      Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000; 31:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/74\">",
"      Bracale UM, Corte G, Di Gregorio A, et al. Surgical repair of popliteal artery aneurysms remains a safe treatment option in the endovascular era: a 10-year single-center study. Ann Ital Chir 2011; 82:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/75\">",
"      Dawson I, Sie RB, van Bockel JH. Atherosclerotic popliteal aneurysm. Br J Surg 1997; 84:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/76\">",
"      Johnson ON 3rd, Slidell MB, Macsata RA, et al. Outcomes of surgical management for popliteal artery aneurysms: an analysis of 583 cases. J Vasc Surg 2008; 48:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/77\">",
"      Laxdal E, Amundsen SR, Dregelid E, et al. Surgical treatment of popliteal artery aneurysms. Scand J Surg 2004; 93:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/78\">",
"      Shortell CK, DeWeese JA, Ouriel K, Green RM. Popliteal artery aneurysms: a 25-year surgical experience. J Vasc Surg 1991; 14:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/79\">",
"      Blanco E, Serrano-Hernando FJ, Mo&ntilde;ux G, et al. Operative repair of popliteal aneurysms: effect of factors related to the bypass procedure on outcome. Ann Vasc Surg 2004; 18:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/80\">",
"      Henry M, Amor M, Henry I, et al. Percutaneous endovascular treatment of peripheral aneurysms. J Cardiovasc Surg (Torino) 2000; 41:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/81\">",
"      Gerasimidis T, Sfyroeras G, Papazoglou K, et al. Endovascular treatment of popliteal artery aneurysms. Eur J Vasc Endovasc Surg 2003; 26:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/82\">",
"      Tielliu IF, Verhoeven EL, Prins TR, et al. Treatment of popliteal artery aneurysms with the Hemobahn stent-graft. J Endovasc Ther 2003; 10:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/83\">",
"      Siauw R, Koh EH, Walker SR. Endovascular repair of popliteal artery aneurysms: techniques, current evidence and recent experience. ANZ J Surg 2006; 76:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/84\">",
"      Jung E, Jim J, Rubin BG, et al. Long-term outcome of endovascular popliteal artery aneurysm repair. Ann Vasc Surg 2010; 24:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/85\">",
"      Etezadi V, Fuller J, Wong S, et al. Endovascular treatment of popliteal artery aneurysms: a single-center experience. J Vasc Interv Radiol 2010; 21:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/86\">",
"      Mohan IV, Bray PJ, Harris JP, et al. Endovascular popliteal aneurysm repair: are the results comparable to open surgery? Eur J Vasc Endovasc Surg 2006; 32:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/45/31450/abstract/87\">",
"      Idelchik GM, Dougherty KG, Hernandez E, et al. Endovascular exclusion of popliteal artery aneurysms with stent-grafts: a prospective single-center experience. J Endovasc Ther 2009; 16:215.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15221 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-EF0CD76C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_45_31450=[""].join("\n");
var outline_f30_45_31450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1231031721\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031427\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031434\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031441\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031448\">",
"      ANATOMY OF THE POPLITEAL FOSSA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031455\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H604915778\">",
"      Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H604915890\">",
"      Anatomic assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H601500443\">",
"      - Suitability for endovascular repair",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H601500472\">",
"      - Proximal and distal circulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H604916299\">",
"      - Coexistent aneurysms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H604916154\">",
"      - Availability of conduit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031484\">",
"      Medical risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H542106921\">",
"      OPEN VERSUS ENDOVASCULAR REPAIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031506\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031514\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031521\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031528\">",
"      DVT prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031535\">",
"      Patient counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031542\">",
"      SURGICAL BYPASS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031558\">",
"      Aneurysm exclusion and bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031565\">",
"      In-line reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031572\">",
"      Surgical complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031579\">",
"      ENDOVASCULAR ANEURYSM REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1300235131\">",
"      Stent-graft placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031593\">",
"      Stent-graft complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031600\">",
"      PERIOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107105279\">",
"      Extremity compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031607\">",
"      Antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031614\">",
"      Graft surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031621\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H779515438\">",
"      Definition of terms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031628\">",
"      Surgical repair",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031637\">",
"      - Bypass patency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031678\">",
"      - Limb loss following surgical bypass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031685\">",
"      - Mortality following bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031692\">",
"      Endovascular repair",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031699\">",
"      - Stent-graft patency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H542127374\">",
"      - Limb loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1231031721\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15221\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15221|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/51/30513\" title=\"diagnostic image 1\">",
"      Ultrasound of popliteal stent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15221|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/13/18646\" title=\"figure 1\">",
"      Pop fossa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/60/26566\" title=\"figure 2\">",
"      Collateral circulation lower extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/53/41815\" title=\"figure 3\">",
"      Medial approach to open repair of popliteal aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/22/41317\" title=\"figure 4\">",
"      Posterior approach to open repair of popliteal aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/40/32384\" title=\"figure 5\">",
"      Endovascular repair of popliteal artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/13/37074\" title=\"figure 6\">",
"      Types of endoleak after endovascular repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15221|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/47/41723\" title=\"table 1\">",
"      Classification of acute extremity ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/1/34844\" title=\"table 2\">",
"      Antimicrobial prophylaxis for vascular surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/9/33950\" title=\"table 3\">",
"      Prophylaxis recommendations for vascular and IR procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/50/23341\" title=\"table 4\">",
"      Caprini risk assessment model",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=related_link\">",
"      Complications of diagnostic cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=related_link\">",
"      Complications of endovascular abdominal aortic repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44376?source=related_link\">",
"      Indications for surgery in the patient with lower extremity claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=related_link\">",
"      Management of cardiac risk for noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/17/35098?source=related_link\">",
"      Overview of infected (mycotic) arterial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3400?source=related_link\">",
"      Patient management following extremity fasciotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38921?source=related_link\">",
"      Percutaneous interventional procedures in the patient with lower extremity claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/63/3065?source=related_link\">",
"      Popliteal artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19370?source=related_link\">",
"      Treatment of chronic lower extremity critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_45_31451="Alfredson's rehabilitation of Achilles tendinopathy";
var content_f30_45_31451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Alfredson's intensive rehabilitation of Achilles tendinopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       1. Eccentric heel drop description",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       a. Stand with the heel of the affected foot beyond the edge of the step or platform with the foot plantar flexed. Slowly lower the heel, bringing the foot into dorsiflexion.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       b. Perform the exercise both with the knee straight (gastrocnemius) and with the knee bent 45 degrees (soleus).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       c. Avoid concentric exercise by raising the foot back to the plantar flexed starting position using the unaffected foot, and hands if a railing is available.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       2. Number of exercises",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       a. Perform 3 sets of 15 repetitions with straight knees, then 3 sets of 15 repetitions with bent knees.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       b. Perform this cycle twice daily (180 drops/day).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       c. Continue the program 7 days per week for 12 to 24 weeks.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       3. Exercise progression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       a. The exercises must be uncomfortable; when heel drops are no longer painful add weight by using a backpack, dumbbells, or a weight machine.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Alfredson, H, et al. Heavy-load eccentric calf muscle training for the treatment of chronic Achilles tendinosis. Am J Sports Med 1998; 26:360.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_45_31451=[""].join("\n");
var outline_f30_45_31451=null;
var title_f30_45_31452="Initial reaction severity vs risk after VIT";
var content_f30_45_31452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F51249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F51249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Re-sting risk after stopping venom immunotherapy in relation to severity of pretreatment reaction (PTR)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Author",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        PTR mild (I-II)*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        PTR severe (III-IV)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle2\">",
"        Number with SAR (percentage)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle2\">",
"        Number with SAR (percentage)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Golden",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        1 (10)",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        5 (28)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keating",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        2 (13)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reisman",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        3 (4.5)",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        7 (15)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lerch",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        1 (6)",
"       </td>",
"       <td>",
"        183",
"       </td>",
"       <td>",
"        24 (13)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"        &bull;",
"       </td>",
"       <td>",
"        <strong>",
"         123",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         4 (4)",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         263",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         38 (14.5)",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Grade of severity according to H.L. Mueller",
"     <sup>",
"      [5]",
"     </sup>",
"     .",
"     <br>",
"      &bull; X",
"      <sup>",
"       2",
"      </sup>",
"      = 11.32; p&gt;0.001.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     1. Golden, DB, Johnson, K, Addison, BI, Valentine, M, Kagey-Sobotka, A, Lichtenstein, L. Clinical and immunologic observations in patients who stop venom immunotherapy. J Allergy Clin Immunol 1986; 77:435.",
"     <br>",
"      2. Keating, MU, Kagey-Sobotka, A, Hamilton, RG, Yunginger, JW. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol 1991; 88:339.",
"      <br>",
"       3. Reisman, RE. Duration of venom immunotherapy: Relationship to the severity of symptoms of initial insect sting anaphylaxis. J Allergy Clin Immunol 1993; 92:831.",
"       <br>",
"        4. Lerch, E, M&uuml;ller, UR. Long-term protection after stopping venom immunotherapy: Results of re-stings in 200 patients. J Allergy Clin Immunol 1998; 101:606.",
"        <br>",
"         5. Mueller, HL. Diagnosis and treatment of insect sensitivity. J Asthma Res 1966;3:331.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_45_31452=[""].join("\n");
var outline_f30_45_31452=null;
var title_f30_45_31453="Lead exposure sources list";
var content_f30_45_31453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lead exposure sources list",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Lead mining",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary or secondary lead smelting or refining",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scrap metal processing or recycling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiator manufacturing or repair",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lead glaze or frit manufacture or use, such as in pottery making",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Battery manufacture, recycling, or repair",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Construction work on pre-1978 structures or on exterior structures such as bridges, ships, or water towers regardless of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Welding on painted steel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Power operations, such as cutting or sanding, on painted structures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Abrasive blasting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Demolition work",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bridge maintenance and repair",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Shipbuilding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paint removal on pre-1978 structures or on exterior structures of any age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lead abatement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rubber products and plastics industries using lead stabilizers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cable making, splicing, or stripping",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burning lead-painted wood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Auto body repair shops",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Automotive repair shop or junkyard work involving welding or other operations, such as power sanding or cutting, on lead painted surfaces or lead batteries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Furniture refinishing if paint removal creates inhalable lead, eg, power sanding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Making lead fishing weights (sinkers), soldiers or bullets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indoor firing range instructors, custodial staff, inspectors in firearms manufacturing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lead bullet manufacturing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leaded solder use (welding, stained glass production, plumbing, valve and pipe fittings, jewelry making, electronics)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retained lead bullet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metal casting or other foundry work",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lead grinding, polishing or buffing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Potential for lead exposure from eating, drinking, or using any of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imported or glazed pottery such as a Mexican bean pot",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foods canned outside the US",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imported candy, eg, tamarind or chili based Mexican candies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Home-distilled alcoholic beverages (moonshine; liquor from homemade still)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imported lead-containing cosmetics, such as kohl eye make-up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pica (ingestion of lead-containing nonfood items, eg, ceramic, plaster or paint chips; soil; primarily considered in children but sometimes occurs in pregnant women)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imported folk remedies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ayurvedic herbal medicine products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Mexican folk remedies such as those used to treat the colic-like illness \"empacho\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alarcon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Coral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Liga",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Maria Luisa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rueda",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Azarcon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Greta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alkohl",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Nutritional pills other than vitamins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hazard",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pay-loo-ah",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Lead-containing remedies used in Asian communities including",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ba-baw-san",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bali goli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chuifong",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ghasard",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Kandu",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tokuwan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Middle Eastern remedies and cosmetics include",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alkohl",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cebagin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Saoott",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immigrant from countries other than Europe and Canada",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Virginia M Weaver, MD, MPH and Bernard G Jaar, MD, MPH, FASN.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_45_31453=[""].join("\n");
var outline_f30_45_31453=null;
var title_f30_45_31454="Sex hormone production males";
var content_f30_45_31454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Sites of sex hormone production in males",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 240px; background-image: url(data:image/gif;base64,R0lGODlh4QHwAOYAAP///yMfIAAAADExhe7u7ru7u8zMzN3d3aqqqpmZmVVVVcjHx2Rko5iYwkRERIiIiJGPjxERETMzM2ZmZsvL4Hd3dyIiIsklK1pXVz09jEpKlNjY6HFxq4uLur6+2FdXm7Gx0eSSldXV1ePj49ZbYPHx8XVzc35+svLy96SkyeXl76yrq0xJSfHIyj47O89ARYOBgbq5udlpbTAtLZ6dncwyON12euCEh/TW12dlZfjj5Pvx8e66vOqtr9NNUuefoispKTMxMnd1djg1NTw5OgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADhAfAAAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgQXYBEipcyLChw4cQI0qcSLGixYsYM2rcyLGjx48gQ4ocSdLipwDQBFQoNkHAQUMOXDIzIKAAMpSecDoTMKFYBQEEXhKK2axAzZsnU/Yk1lLoUJnLaNo8ppNTVWY8WUIVSkDC1mRGpxq7qomssqxMvx7sqvZYWKQ5/5VqdTrIazMER6kmfYZ2WFO6AIgywyu2mFlMh5H1FfYTMNuiecfujeShQQMPmRh0KNSBwSUBCiZRGE0BhaDOk1BP+hm0EwrSFDbc2sAAxCEQDGSLenwJtmkAqiMFp0T40QbYsWUltrT8EIoPAxhAbwCAwYBKDWwTsv45tKQB4AdkoFD9uiTuq4F6ohA+OiL0q9hTN9RgAPnddi+1H19+EnzikTFiXXueZWYeJc0hGEl9mwGwgQcUaDBAA+RRwIFmpoHQgAopqABACgxwgBkA2QniQYgSdjcJeMBN2J+DJ2AoyAYxdvDbiRykmF5rnLD3wWiypdCAaUJ6ICGFKlDoAf8IKsQoI4malfhhiCNq6AEHHMhmIQMMpCAICjFy4CJuVJJoHyn5WcJiBy6iR+OTb9poIooHAljYIsedMMAJyXXGwAmyacihhw1EqR2ZXkY44X2SJDiJo4SAAB4DDQSaQXQgeDAAB2xyUN6lFLDZgZiYuafpBw3oWAloK074gQYecqdCBqjSCsCstX4AwKmp1gkJa+sNoIFlFe4paQogXFobe8pSQKmeJ7TIQX2eiUpqeRpApwGJJxQ6gG3QdaAndZz2muSZo6RZCXgNvBrrdbg2YGu8tvKqqp0LuijIsB1ksK11oHZKbYujDoCssto1Otkj8oZnG3piWpaidb/ZisL/pgC4J+a7Kn4X3ZH9pTAAZmxuIDLJA2yw8YuSNBZsePOJnIGnL7LXIAAgxOiesIK4ZzHG6EEHAAopcDDdBnsCIN+thUpIQX2MhqIuJZOCzN3JLZo8ctYr/zdJcZDUN5/SnV1a3m88Z+yZv5a553UkkMIdyW8bsOkZetZZZhnL7qntN96+SsKqxz1fxx3UZj59JtSAUwJsJ+wVOIgK4GmH3tIER+633327bR53H2SQgsgUuigfrjnbh3i6bUXCYsaGX4c41LPb17glYDOsr6YiCg1f554Jq/fDgUMSt/ELLjtueR5ozQEFHkQLH6n1eeme2EYWD8ngrtsn8r/XIf28/wYZOLhphOVjfy8kD6gHufAlPpcBAxnIZl3zmN8vqWfQLanxyNV7EXeEFaoJocBfBSzd86yjuKiBYmqtosD3+iM+9JlvfOmbUPYukYAANUJsglBf7AbRv/0BIGIU0BDzdKOwuEDCWeAZloku5aVeAe1AKBBTBhrkHhRYRwPrE5wDWjUp+5kHBBL6gG6QOAAlDu2HQXTE43pEIADoqTS0QoEHaIi5DSjLPRuQkHU8k0PxNKhxkorOmL5IHT3RSnXoEoVg1BSe3LyIiU7EWRJl40NhRRESuXMECIemrYkdKIxqJOMJLpUB6mzRYApy4U6GSIz28SgX0FPczY4BwWMEcv89EGIQKI73CFL+QgCUHIYleZHGDJzgN8iYozI+2YlWvnKUC8NKKoWxSrrIMhm0FIYpGzHMXqCyGL10SieN0cE7DaOYi4DmInDDQkXQJmGaOGYl3ScLalKDN8toZik0gzM7WiWXm1jdIpLkQEwIQALI5GYrLrehaiyzGOIkxfXiWBZ0EiI7IJpPdjZAHRR0BlAzuhAD2ck08hCNSx2iEM4ugyXdFKoDUmqENlUpz/gcaTT1fBMHbCNSJkmUoSgolIhMdCE+1eKexMhnb2KE0C3JaZ/tvIQ0E7EcM4rJepe6TujalQEVzKqRDFza0qzTgX4tVVjaktbAHLFRXnZUFcn/whTUKIeqE3CAqw3wqlJdNFTobEBS05rWS1uHTw+KpomFusymOuU3dfZTkofo4c50Zb7NaGp030rcWCuVtFs9VRBCS1vfNArPbR4AFuiBGtI00IEUoGCylX2N6SaEtGdNSGSowqYsYDqMYEZiZbeKWK/qys9M7BQRPS3Qzgo02NqNZrOlG9th+wO8R1Q1GO177Csie6YTXUpXxm3iYCOnN/J4awCbjMUvkSHTSvwnb3pjbU6Z489BKFdP1pMcAsV0nPMxEGlIdVEGMuABD/yoTZ8T6shMSNXGclS4rrgfQe1DgRNAaL39/W/9xOMt6qwXBBIEQQo6kEKM0WK6x6gu/yVExifLiOx50dNuJ157iJ6uF7o9k9wGtKUdNr2RPGzSwPJUNqndcgeRY/StBC4JjODC4pFCso8KoNPEDewYPE5M8YrFJKz2SmhTsBwtW7fpzEn0ir0kOrKncLrh7ob4FZkUZX1p/Asb04W0wpDwM628uVbYMsmLeGc88SsUCDPTrcIkszHeyWVfdJDNL3FzW5scDA4bws+2oHNMBYDng+h50HwGBqAJsWhaCHoYdwYMmIEL5z7LuRiPDjOhJb1kSFda0Ze2Zo1Mw84lOQhLlvGQnxBqpYpuQgAWqHMvIu3LTms60b9otCCgSS9dMSs6R/UWefjlL2xFNZuxHnShDf9yaE/j2he6BgA0sVYym4UwsIgLFf1GCAChIVvWvKC1U5pt1Wf3ItrQtC3mbMs793L7batKtqeXXRByB0PMccZrJCpIPqXtzrxwvIwhBQFvSsAa3LsQd5ttfe9P5zrUicCjlvTVohM/x4/v1t4kDj5oAwDG3sDoYDLQLYoUQA86aB4Fxz3t8VrfheG8IHkojvyBEZ0C1m1t+bhh/guRw6XKfLFAWwETGJ7b2ei5kPlOhD5oooO850jHhdKbgfOmfzzqCce6LaaOlQgM/erNaN/IIS6Mqnva6VrPhc/1ou9l/LbGacfH031xgLjPgutut7sraEJ0Bei9FmL/uVUgUJL/whv+8IhPvOIXz/jGO/7xG8EA3s/yd1YIoPLzuDzVvS74TUSb6PpAOD7H3nZlPEDnwiDAShyTAGcshe1Ad4YDHlCMAjCdLgV4vTIOQPvO3xX0wA++3EqfDAesvrScp8sD5K0MfFua+MhQQO+HUQD7OsUA01cGAcx9brIHwwCi1wUBUO+U8AuD3s+P/V3ID4wDJMD8/8A+ZLi/i8knQ/q1lwD7DVKA7M8S/rpgf8hwAABoC+MHegXoC/RXf94HDAiwf75AAAhAdPI3EwqAfg8HfZx0fMJgAA6AgQKRANaXDAdwgb7nWtDwABNIDLyXgPtQgYPhglvXgL8gg7QAggJx/4Az8YEniBjQUAGt1wkLMIRDKAgiAAEQsAKc4IE4uA1EWIQAcIRJGAkGoAATgGdVyAhPuABGiIRKWAsGcIWPsIVdOIWRMAJPOAJRSIRqWEo06AtAaIM8tRC7phAwsAlV2IS7B4F/RofSZoeQYBTvVAE2ERQE4H8d5ocLcYeGoIefoIOOwBB1mBCMaAgQ0IaFQHgKAQEAIHmAGIlv2A0JQYSCoIQikBD1YAE8sYKKMIpQaIqoWAjgVgARcHmXpwDeQUwBQIoAAItkQQAWEISr4Ih/yIu+CFtcaIkBYAJDqIaStwAjEIvEFIq8EAEKIIewFQBeSAjR6AKNaAAHEI7iSP+ABEAA4ViO5kiAANBBQSiO6JiO5OiO41iO41iPBwCO9oiPBrCP/NiP/lgAABmQAGkAAlmQBhmOfmeLlxcBFVBnCbGNg9CNhSCICrmQqliRCikBwpiNECkIEjmRl6d7qOB3FsB9D2mGHhkA3thhyZiJAYABSOiMu3iKKzmNGshMfJgIB4AA6LcQGEAIORAAMVAIHigAQAB5SMkRRICRtthkPgmUQlkI7cOUVImREtCTCvGTgxCUQ0mUtshm5viOYjmWZImO7giP5wgAUxkBDqAAxgeBT7mVUUkImpiVLqkQXOiJATADIuCGN1kM4bd9CfAAE1CYtciKfVgIJSB5X0j/CAdQAQ5QmJKJi5OJi7jYlpNZAW5JmYXZlpTJmRPglpFZAZI5ARVAmqV5mqpZAQ/Qmq7pmgkwmA8Qm7QZmwhAmwiQm7mZALrZm75ZAAhQAAT5E5dnAVYYmfsnjYKwmAHQmINwAKFpmdI5AV6BkbX4TgrAh8oJAMzpnM9pi69XghEgAQ4gAeTpluaZnuq5nuzZnufpANdZkdmomIxpCGi4AAFAAwvQl3SpjYQgeTCQEPxpk+rHDBLAgYfQQUypndqIhAAwAizwkjG5CYhJDRMQAQ9gbifJiRAqoZf4CDRRkQoggsk3h0jIoREKkx9KCCG6UQdQnbUYARZgAREQozV6/6M4mqM6iqMzepEKWaOts6EPmqIT+mct2Z8qmpe7SHguUAKg+JfEgH+KUJ22WKLZqBAAgJ8LcaSWoHrYGA2SqKV4+QgU6QAFUIBhyhBc2qLyVI4AQGM84qafAWu5iXBpuqWHgAED2p+b2Im7CAARagJPWqDVoHoVGQEVKnyksJPgWAoEoJA5+YgTwJNf+goCuIGFgAAP4BUWMAEJEKMLaAoFwIN08amV6pVNmQoeSHqEehZLQZAtAaqCgABmagsIEAGRGhC0eqqOqZChqgm52n1QagzECRq8qqjCkJAOBwoIcKytcKlzdnkS8ADq2GUCsJHX8KIRQIyd4Hfc6gjVmf+ooyAVPahTg/EAMTGawWoLj/mtv0CQBZAAhUmaDgCfl+esVIiImjCV2FoKZ1qu3IUM+5gAPrqugPEAQMqUFmCw33d5+toO0DprxVkBLceaexYNbCqisNAS7soIB6CK/TquuAqwlfB5pUCcwXgnckoMDDsMMYGRCOoMbBGz7hCxYPgAFSABFtCWTVatLBgNBaCsCvmwjSgENBavHSuLLQsJMSGSpCCB+LoKNhsLBImuMzqtipAAv3qDFZC0uLB9UykA8SkARGsIDxAAeOZ3ISsJQRu1guB3uWgKBCCGsHdOi4ADLZC3eYsDqFCOtCi2I4qDwVkM7ue2rVCCCpkAxVr/toZQAWhbCDHBuI6wk6Hgd067qKxqt4pAAhfQuZ1LAo0QAhfQAl1KsGxpfAvos8PgtbXwt7boAIbosJFwtngWkpkAiZ5gualwiIaLChGLtzZwATbQAnzbAjJAAjewAwCwAzdAAiQQAjrAuTbQAwCgAzZAAjbAt8zrvCHQiAhQARYgAWy5tRUgrr6Qh8cwt1SqEqh3m5JAuyxqu5jQtqAAt6o6snXreY4gut0LADxwATJwAwAMAC9QAyFwAy+AAy9wAT5wAzpQAz4QAjVQAwRswAg8kaYZmg8og0BYe6Q6DBL4srA2AVuLCPA7CIIYt5VgAA1Zv9wjt3QrGcPKv4Ig/wMXEAIhsMAAMME2AL0AILqk+wPCGwKc2wI87MOEgABYewnCCZjmywuH6KPWyLpS+biDkJCIigm4260vbArNSrKRxAg0DACci8M4DAA4IAMLXAM6AMQ/PMQ4rANpvMY6ALkq/DVLOwuFq2lD+wkJYMUAgBcKiQnuV7ld/LQmmL+/twhjLMQy0AI8YANk3AMtwLk4wL/Ey8A80AI3gAMkQMmWXAgLWaM7i4vlC38HWgy3msesQABCawFf/AknDAAtMchMfI0ufMejQAAfbBgQN8Y/vMADbMMX8ALUqwMLLAP+6wOd6wM6QMzGbAjre6jnacoJAH6N2AgrSwvbd77ga/+LwUjFinC2OleCqtjLlSDOiGC/qpq5+nuzCmCeNJqwChuZs5mb64qua8sOEhifxtm7g0DOUhkE4myOhqzLoxDLMtyquGC1Y1uVxjkB97x/1VmrjyACW7inmWB7rNwIGP2EGt0ICmqLkrsJf4xnCBAAJdy4m7YIH02EIX0I7HwKb6HIKFgMLFyY8fzQTEmenvqpP0qtjaCXCaGVm7DFhzC3sCsJRP2Sj8AWrwvQCQrIgjABAfDEn9DURq0IM30LLz2EMb0IQ+ikgvCEZB3GmosM5kiQn2qc8VyVTDm+Lr0AJrCM+7kKjwpr0reAGF3XzBjWhZAAChCfvLkKf0x+CnD/1ZnAwuHX13YN2ITQ1aYQmY6g1YewooYQA5Q4CAzRlY9CjQmnc4Jdr/UqvnBNtlgNAITHiZ7wmIxAkcWptfS32o2Qe1Vq0YYdAORn1antCEqsh7TtCJJdCiEJkBjo2H/NkohQ1yrJ2SixAk6N1u+sDa582gKQk8Gd1Pt4j/DKjwLp3fjcEiQMnLapqawp2FUZnM+W3Yrwo1LNCCddCLytCuy9CDONjm9alvptlvCIlml5AGNbvjyJCPXNaFy6nAGQA1xZhwBAA8tYsqB9DAbA05Hplg+AcAU+CLVs3Rze4daJ4f7JCD+B0Kpw2PKt2JiAffCX4evMPYMtAaJJ2m1Z/6+XSZ4yTtrmeePrWa9VOWOXHeJ8apeEAN0rAN2C+ocJwQJn3UIMjQwWQLNJfHmsecoAyOKB/KMKGb49uuXhK8+e6ZnSeZrTbItWqLWLYOWFoM6ZEN+EMN+YQKvADeSMMNPfy5u7Wd69CZy5aZDf3d3+KLQwPqkQWOD3mZ93TQgRygIRGgBOSokqueTD1+SeFKnY19uJgOYHIJzh2I/kuN+NkLGFeeGOgOa4wOYajuKE/AikHtmHvKj1KtE4aOV/WginqKIRSgN/6Kc5AOHDmnrpywh5XaNQ/gymXtWo3qUdPeeo9N6E4MqhauV6aggB2pWazQK5PgIz0JzSvchYQf/ivGBazzmi2mDibX7sldA+K63sS30KNJHsyhHhuaC6vo4O5H7qlv4Kfrfu8TC1HcjsoeDu0lDvxn7vi1AALfwJ+e7vgsDLAA8L/B4M4s6yiWwOAk/L5k4J6O7C+l4KNEHwSQfvuECITpwOFW/V6X4Kw12zIP8PCh9mun3iHp8Iuafm8i22LV93J//uvQ7x+8wLTEjvL1/uMY8IYUjzbS62Rr8Irpz0qvDwwGABJY0LHA30u33xk9DNoBCrLf+mkhCOteD0NXgMTN98QW/vmbDHCH95Y48IDB8JM/r1K28LCjD0eizq51DyVs+2B+8JtUz3ldD224N53D74yjD3hPv/flQP87eb81l7eT3/Cf8a+HC/8+239Z2w9siQ0lXv99kMCoL4+J5g949Qo5Mv6cYw4MQggemg+YpPyArdCYLI+VfvAC1L+rQA9r4A9TiNzuPA+kJ/9q+/hI6fCogPopfXqDpv+oQr9qtf9gN/uw2PCHXX6qIQ/Ikw4VV63cmf1sxweoS795/g9aXl/BYv+88p1I94kaB/1PrnCBkrAOY/3dy/DBpZexaA+W6JerzXC74PCACCFQEIgoeIiYqJBg8Hi5CRkAQSApaPkpmaiAQKBpuCD5ajBKCmp4kBqKCqq66vsAAGpbG1tpi2kZaGhxYCtLnBiwgBn4iEvMLKh5Sj/7/Lws640Kuty9bU2aCz2t2CBMnZDhIFhwiW3sHExocPAeW2BZ7a56PT2gYCCafO6afYwgD6Gyhh30BoBSTcW6bAAbsK6A7CWpfIHbxaBxx1GxUBWDcCFRZKqiTAgkRNAnOlPJltQjiWGCt4hDbu4gRL7GCConisULCZ0BRYMolqwQp/9SrohLSyVtOlUKOerHlIqAAHQKUm4nmI0MVYBxKIFFavIyoIGFblM2gqgoCvUp/Ckqv11dW6rhK87aaAnCC9Q7PiBcA11LtcBSbkpGnJ7Cm0rhAI1iVgrE66rjAPNlXA8uZFBODSlGDM7Si2nwUVBmDxpzeOkxUFmE17wf8pbqcqKNisGVXv1JIQeAbOLEFsW+OM3Rz18vPq1rYI4KYmatRiSQsWmGCRvcQpxagIHGf521R54ooETECfSa9oZVQFGeg7XGuBw4ig1zIQMhsBX43Vlwhkq0jG3ibnIXjgggwmkhwiBqx3IDFw6UdcMwJI4MoKMDQITYIoefjdewzOJyAsD5ojIXsUJpIAfvv1R81/lqDmDSUkeghiJjuyJ0FzDZrYTYp/7TYhjH8hCcsBBlJzgCVYSVTAeAf2GImVxE0pYiInokgaIgkYyaKSL+aIVz76bKkVlouwmdp1HobmDZGsiYlei/kp+Qp/cOaCpo03CvCAmqlQ4+ZnEQz/SmgBFnTpCp0P2JllMRXp6UpYjt5W4yIj0AABDSMAMMICoQKQnSDZdYdIDBBAEIN3EBJa6IeyZvJAnwuCM+eXhyTgwIL3VWjpKtJR6UoBmyayQgAuYDCDKhAEAIEgs1FL2wy2lcACsxgEkBYiWoKSqm2HiLCAdyUsIIKp45KKSrrkAgDvqbNeU6skmX6WLyrxhSIpcHj2Omx44UJTT3OzwTpttNMCUK3DqsAgLQAmBGCCICXQwIlfrFx7FADd2raAtxDTNnEiIzS8iMQBxICqyTOUSq2h90aSqKwFRLCvKXSGuWDASZppSoS41lIPoC4wa8IK3kWLQasPzwYBCy6E//osrItUUHQqqoywrW0hm0pydtvS4G4iI0eStMUvp1Wxyg7TXPMit8qqazcJyFjkzz6BOXB42iCbZiIidDsbCyVEa3Irs2GQ9LTVKv7tIdOh1MqyOYBsMQQVTx72ImkvEkMANFwtdlo5BPDxzLTOrcjW7En3kQIWhOPzgfctVmYuoRm7iuCAohtD0gswbO3xEAPwdackg9nlwyOnZThtngcQ7yHTS51IxSNUfNTItF2MyKHju66I1rIKSY0BDljyYzu/HkiAQLvHo4DQsAgu2gwwLBDDDDNI3MmiZj0aMAsAo3PBCgw4uUHA7hAPW9bFwhY97FlPEeYyYHZkJq/GJf+NBWJjQbcyV77Wme8QE8AfcSLkO1RUZxTwA9YQ4FK//WiEGvVYiAnWloN1GS95JfPWuhC4rQCwQGPg8t1sjALAUFGweZq7HiJClwgDmqBVzzKXt0rwLCSyzl4nPMTO8NJCVDxpFGKK1IEgAiVc1DBLODmJcMxDmx4K4onVk2K5GniIbcFKYv0j2ehmMMS4mTCMdVuUQrSxnEb1Kn7ocUZlBKZCTYTlgceKo0TQdy/yQTCMvcJkajJSxlMABpIAuF0kR6Ehc/zNFAQ4QClBob+TVI5QnvxiGMcIykWgyU5qZE/OkqWaV9rHEpUUhixrlktDglIsOHMALzXhixWxppX/7GmfAGzXN6PVLhuCA5I2KKGoWjWzmVq5n6wOIJNu+AI1FSCKj0riImNuonfg3MVJZvmZc/YSAAXbkuz4witBFKCc6PEFKlPZzf0ETp8SSYAoiePPXkKTUOzkJy0D2qD2SYoY4kRFhJKJinBKhBKA2lJFQSkoWellov+EhDyUggigwWKkoIAXZ4g5EI0OZqUxDapQV8HHgbDMZZsA3kk6w0y5gXKOGH2AT4faDXmENBFrE58m0HRValSgqwsC6gkdANYVKmCaVAWnOjUxutIFAGuS4Kotp7omp4aRrmnNaza4571N/GmfcxOr+TjqofngVa/C0Is1IVECDxoxqTxN/wcBIjCBwy5FsHMjQEsJZVjEDmaZmbAiFgNQyEj89aSBtaskdtCCFiziBiQQBglukIt5EOpumzgATD9bgURqpVia8KMgALnVyKbjAGiNi2ojcYMLXIAHiiDBBYRxgdiyR6f+EaVQUqoJ7OoETRFAAP7adYh0cTAWCeGuLU57EAVItZPLhcQLnGuDQ/CABDKYLwBaEAIc9MC1LZDBbHcAgBD04AcksAGBA0wCEvxAENUFwA5gS4IQPAp/vjgrKo6ajbCYwioloSkoOKwTzTojAhIQsWxMhqrUwW0/lmWEcW+U2kNGggcX+EENLkBgHPsgBPoNwQV2HAIcy6C5MgCAc/99MN/6hsAGIZBuD5Qc2xfUIAQ3eIE2TFMSByBUElkFhXhOgU9mINcAaOZGArjcGAmQVRaTCTMk8hGBOtv5znjOs571LEmOuGWxS6QXbV4ci1sKg70DYSp8bQwJG1xAB46esgweDQDpFvi5gph0CIA83QjvwNM/kIEPLmDhCNegBlDWgWl7i4AEuPrVCGj1Ax7w6lknoNXalKQCJvCAWGelrabLhAMsYAEJGPvYEiB2sZNNbGMr+9l5JnafJWmBCPQJ2G+FBGCmze1ue/vbKoZYq1b3w1tINJ+DO4h4m8poRXy6uvP1QaWnO+9Lu3bem940lSEcWx/U4Ac/IPW+cZD/3yGrWhGT/bbCFf4evqpOEwuPuMT7PBaHr44RdX62sh3A8Y573OMNcYACRk7yXVeAJJKMQEMAZbLJlZsTmQoLSU+hVCnttp/xTUTAoRyCHeNAyEUO8gXuHXAZtIAH9Y3wvi/wghY0t9SxJcF/pYuDRZxx4lgvaHkdC8JMVEDkEwi72CtA9rKT/QG9RXvaZ812tt96Amx231cNjTGu60Rwo5j7lQTy8kN4FHDoLqsyDJDcqGA2EaMmMACae4MdSPcFQr93ged7gSQrPcI9cK50oQ6ASTN9ypBAQG8T4HbSq7zVpKd16mMNYmdUIAGKVoRoIZBFJ/FsFF5W4exrz5Iz/yqmPlJrFaoqZgI9csQCKuTPzIc2Y7w1SVaHrxl48OWMCbg6uNkGAHERYoqbuMR3wtV+ADrEEgL0mo60sVb6K5JrASignZE4QArRrV5wFh4q0b+XCh2QqPrDRE60JHie9Q1hwmUWIFEeESHMkA2AIYDBgFzsBkagRFiJMFCfAYADiA9w5wwcY2KKEmPHAFEHgXb3dxk5J30OuBkJUYIZOGftRw7LIQCUxYIoJIIDMQG2BX0neC9vxlmV1YKS1QhxxxHaYBUpCIQlJIFhRHcMgoFI6A380X6nkQnkhTFnswhrpknqtnw4125zQ4EMklFPeBAx6Az/Mj4sZiouFnqsBP+C1OQQ4jIu5XWFpjAqqRIq5rJB/7CDteJ+LiUANzeGj9Jt3BVo5DJokMCBbphUArI4LXYyiwAB5yUIiqM92UN+CuKFNbOIgghK4MVt8oSG43YIfXcIzhAlJyEUEeAAE1ABOWKI6kdoEKRHABAtxecuITMCD5OJSnhCoKUmBOB/nZgLTCJRCIB2s9ZbvrAQLUeKkJgIXCZiEWJyZBd2ZYeD1Rh2JbeN3FhyEyCF7tODoggB5PaMqUCLTtMqTmQ9InBArMCHsuKKsoIAOjOMUAFVaKgIpSgIXJYML4R1AOlt/9KMlGiOtbg4fFSJFzQ9hGQe8GiPENmCwdcw2mExtNj/jzCBcigWUrvojIRmh6SjLgPyjN3CMqXFIw+pJhEgjFniSBF5XK/HI2noiOlBCjDxjVNyHBM5fBbJFOjoLa0CNtYTLS4AV5KQf7WyVmpCSi/pD78YDZZwhrwxk2moCBhwkgWJiGGzLVqFkprYlGBpPk8ZDBmmE+u2aL1oPpykJgnBiWEJAATQiiDIhP4gARHAhT+VkluykjiDTW/5l+aDlIA5mB5Cg1GhG4GIF4JJKDdEKKpEmE35ANOng19pN5u1lJUAmZqpJou5mbzjmS8ZJolZF525JRelJgjgl6B5U8ZxQsdomBJRmiKSg1tSAAu1mpfyfHOjW245ELLpIae5/5S4GR1LqJucqZciAoYLIobD6QrgcITskQCTiUvI2SBxOZpRwT69CZahgZcrhI/UWZmy0phb4mHN+QoQ6IvKySC/GSTb2Q3meZ6roFthJHrYqVziSSjG6SFtKZ+/A53oYQDgeZz5KVDBKSK45Z+w9J7lF4HKgE5SQZfyA6DnWQAUChy+cqF1VaAISpvJKQEMGpHg0JqD5VvhmZaZxTFsiYoKKmawiZvt2aIy+pknlADvY06Gsjg6uqM82qM++qNAGqRCOqREWqRGeqRImqRKuqRM2qRO+qRQGqVMOqNUWqVWeqVYmqVauqVc2qVe+qVgGqZiOqZkWqZmeqZomqZquj2mbNqmbvqmcBqncjqndFqndnqneJqnerqnfNqnfvqngBqogjqohFqohnqoiJqoirqojNqojvqokBqp9hgIADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sites of production and metabolism of sex steroid hormones in males.",
"    <div class=\"footnotes\">",
"     E2: estradiol; T: testosterone; E1: estrone; SHBG: sex hormone binding globulin; A: androstenedione; ER: estrogen receptor; AR: androgen receptor; DHT: dihydrotestosterone.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Braunstein, GD. Pubertal gynecomastia. In: Pediatric Endocrinology, Lifshitz, F (Ed), Marcel Dekker, New York, 1996, p. 197.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_45_31454=[""].join("\n");
var outline_f30_45_31454=null;
var title_f30_45_31455="Pleural effusion and diaphragm";
var content_f30_45_31455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pleural effusion and diaphragm on thoracic ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical orientation of ultrasound views of a large anechoic pleural effusion on the right. The transducer marker is seen in blue at the top of the image. The effusion is located immediately above the diaphragm, which appears hyperechoic relative to the liver.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_45_31455=[""].join("\n");
var outline_f30_45_31455=null;
